

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/47, 14/705, C12N 15/12, C07K 16/28, C12N 5/06, A01K 67/027	A3	(11) International Publication Number: WO 99/51636 (43) International Publication Date: 14 October 1999 (14.10.99)
(21) International Application Number: PCT/US99/07352 (22) International Filing Date: 2 April 1999 (02.04.99) (30) Priority Data: 60/080,676 3 April 1998 (03.04.98) US (71) Applicant (for all designated States except US): NPS PHARMACEUTICALS, INC. [US/US]; Suite 240, 420 Chipeta Way, Salt Lake City, UT 84108 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): GARRETT, James, E. [US/US]; 1584 E. 3159 South, Salt Lake City, UT 84105 (US). SIMIN, Rachel, T. [US/US]; 1520 E. Redondo Avenue, Salt Lake City, UT 84105 (US). BUSBY, James, G. [US/US]; 3256 East Del Verde Avenue, Salt Lake City, UT 84109 (US). STORMANN, Thomas, M. [US/US]; 1327 East Harrison, Salt Lake City, UT 84105 (US). (74) Agents: WARBURG, Richard, J. et al.; Lyon & Lyon LLP, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 18 November 1999 (18.11.99)	
(54) Title: GABA B RECEPTOR (57) Abstract The present invention features a novel GABA _B receptor subtype ("GABA _B R2"). The cDNA sequence encoding GABA _B R2 is shown in Figures (1a-1n) as SEQ. ID. NO: 1. The GABA _B R2 amino acid sequence is provided in Figures (2a-2f) as SEQ. ID NO: 4.		

Applicants: Kenneth A. Jones, et al.

U.S. Serial No. : 09/211,755

Filed: December 15, 1998

Exhibit 5

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

GABA_B RECEPTOR

5

RELATED APPLICATIONS

The present application claims priority to Garrett et al. U.S. Serial No. 60/080,676, filed April 3, 1998, which is hereby incorporated by reference herein in its entirety including the drawings.

10

FIELD OF THE INVENTION

The present invention relates to a GABA_B receptor, nucleic acid encoding a GABA_B receptor, and uses of a GABA_B receptor and nucleic acid encoding a GABA_B receptor.

15

BACKGROUND

The references cited herein are not admitted to be prior art to the claimed invention.

20

GABA_B receptors are metabotropic receptors coupled to guanine-nucleotide-binding proteins (G-proteins). GABA_B receptors modulate synaptic transmission by inhibiting presynaptic transmitter release and by increasing K⁺ conductance responsible for long-lasting inhibitory postsynaptic potentials. (Kaupmann et al., *Nature* 386:239-246, 1997, hereby incorporated by reference herein.)

25

GABA_B receptors are found in the mammalian brain, in locations outside of the brain, and in lower species. Outside of the brain, GABA_B receptors have been identified on axon terminals and ganglion cell bodies of the autonomic nervous system, on fallopian tube and uterine intestinal smooth muscle cells, in the kidney cortex, urinary bladder muscle and on testicular interstitial cells. (See, Bowery, *Annu. Rev. Pharmacol. Toxicol.* 33:109-147, 1993, hereby incorporated by reference herein.)

35

GABA_B receptors have been targeted to achieve therapeutic effects. Kerr and Ong, *DDT* 1:371-380, 1996, describe different compounds indicated to be GABA_B receptor agonists and GABA_B receptor antagonists. Kerr and Ong also review therapeutic implications of affecting GABA receptor activity including,

40

spasticity and motor control, analgesia, epilepsy, cognitive effects, psychiatric disorders, alcohol dependence and withdrawal, feeding behavior, cardiovascular and respiratory functions, and peripheral functions.

5 Bittiger et al., *Tips* 4:391-394, 1993, review therapeutic applications of GABA_B receptor antagonists. Potential therapeutic applications noted by Bittiger et al. include cognitive processes, epilepsy, and depression.

10 Kaupmann et al., *Nature* 386:239-246, 1997, indicate that they cloned GABA_B receptors. Two GABA_B receptor proteins were indicated to be cloned from rat brain: GABA_BR1a and GABA_BR1b. GABA_BR1a differs from GABA_BR1b in that the N-terminal 147 residues are replaced by 18 amino acids. GABA_BR1a and GABA_BR1b appear to be splice variants. The cloned GABA_B receptors were
15 indicated to negatively couple to adenylyl cyclases and show sequence similarity to the metabotropic receptors for L-glutamate(mGluR).

20 Kaupmann et al., *Nature* 386:239-246, 1997, indicate that bestfit sequence alignments with GABA_B and different mGluR subtypes indicates 18-23% amino acid sequence identity and 43-48% related residues. (Deveraux et al., *Nucleic Acids Res.* 12:387-395, 1984, was referenced for carrying out bestfit sequence alignments.) No significant sequence similarity was found with GABA_A or GABA_C receptors, or with other G-protein-coupled receptors which were not mGluR.
25

30 Kaupmann et al., International Application Number PCT/EP97/01370, International Publication Number WO 97/46675, indicate that they have obtained rat GABA_B clones, GABA_BR1a and GABA_BR1b; and human GABA_B clones, GABA_BR1a/b (representing a partial receptor clone) and GABA_BR1b (representing a full-length receptor clone). Amino acid sequence information, and encoding cDNA sequence information, is provided for the different human GABA_B clones.

35

SUMMARY OF THE INVENTION

The present invention features a novel GABA_B receptor subtype ("GABA_BR2"). The cDNA sequence encoding GABA_BR2 is shown in Figures 1a-1n as SEQ. ID. NO. 1. The GABA_BR2 amino acid sequence is provided in Figures 2a-2f as SEQ. ID. NO. 4.

Thus, a first aspect of the present invention describes a purified nucleic acid containing at least 18 contiguous nucleotides of SEQ. ID. NO. 1 which provides the nucleic acid encoding GABA_BR2. Preferably, the nucleic acid contains at least 27 contiguous nucleic acids, more preferably at least 45 contiguous nucleic acids, or most preferably the entire nucleic acid sequence provided in SEQ. ID. NO. 1. Advantages of longer-length nucleic acid include producing longer-length protein fragments having the sequence of GABA_BR2 which can be used, for example, to produce antibodies; and increased nucleic acid probe specificity under higher stringent hybridization assay conditions.

By "purified" in reference to nucleic acid is meant the nucleic acid is present in a form (i.e., its association with other molecules) other than found in nature. For example, a purified receptor nucleic acid is separated from one or more nucleic acids which are present on the same chromosome. Preferably, the purified nucleic acid has been separated from at least 90% of the other nucleic acids present on the same chromosome. More preferably, the nucleic acid has been substantially purified such that it represents at least 75%, more preferably at least 85%, and most preferably at least 95% of the total nucleic acids present.

Another example of purified nucleic acid is recombinant nucleic acid. Preferably, recombinant nucleic acid contains nucleic acid encoding GABA_BR2 or GABA_BR2 fragments cloned in a vector. The vector contains the necessary elements for introducing heterologous nucleic acid into cells for either expression or replication.

Preferably, the vector is an expression vector containing elements needed for expressing a cloned nucleic acid sequence to produce a polypeptide. The expression vector contains a promoter region directing the initiation of RNA transcription, and DNA sequences which when transcribed into RNA signal protein synthesis initiation.

Recombinant nucleic acid may contain nucleic acid encoding for GABA_BR2, a GABA_BR2 fragment, or a GABA_BR2 derivative, under the control of genomic GABA_BR2 nucleic acid regulatory elements, or under the control of exogenous regulatory elements including

an exogenous promoter. By "exogenous" is meant a promoter that is not normally coupled *in vivo* transcriptionally to the coding sequence for GABA_BR2.

Another aspect of the present invention features a purified
5 nucleic acid encoding at least 6 contiguous amino acids of the
GABA_BR2 amino acid sequence which is provided as SEQ. ID. NO. 4.
Due to the degeneracy of the genetic code, different combinations
of nucleotides encode for the same polypeptide. Thus, numerous
GABA_BR2 and GABA_BR2 fragments having the same amino acid sequences
10 can be encoded for by different nucleic acid sequences. In
preferred embodiments, the nucleic acid encodes at least 12, at
least 18, at least 54 contiguous amino acids, or the entire amino
acid sequence provided in SEQ. ID. NO. 4.

Another aspect of the present invention features a
15 recombinant cell. The recombinant cell, which can be a tissue
cell, is made up of a recombinant nucleic acid encoding GABA_BR2, a
functional GABA_BR2 derivative, or a fragment thereof, and a cell
able to express the nucleic acid. Recombinant cells have various
uses including acting as biological factories to produce large
20 amounts of polypeptides encoded for by the recombinant nucleic
acid, as tools for screening for compounds which modulate GABA_BR
activity, and as research tools to study the effects of GABA_BR
activity.

Another aspect of the present invention features a purified
25 nucleic acid comprising a nucleic acid sequence region
substantially complementary to a sequence region of the SEQ. ID.
NO. 1 or the perfect complement of SEQ. ID. NO. 1. Such nucleic
acid can be used, for example, to specifically detect the
presence of nucleic acid encoding for GABA_BR2 or a close relative
30 thereof.

Substantially complementary nucleic acid regions contain at
least 18 nucleotides in a stretch of 20 contiguous nucleotides
which are complementary. Complementary nucleic acid form Watson-
Crick A-T, G-C, and A-U, hydrogen bonds. More preferably, the
35 nucleic acid comprises a nucleotide sequence of 20 contiguous
nucleotides which has at least 19 bases, most preferably 20
bases, complementary to the nucleic acid sequence provided in
SEQ. ID. NO. 1 or the perfect complement of SEQ. ID. NO. 1.

Another aspect of the present invention features a purified

polypeptide having at least 6 contiguous amino acids of the GABA_BR2 amino acid sequence. By "purified" in reference to a polypeptide is meant that the polypeptide is in a form (i.e., its association with other molecules) distinct from naturally occurring polypeptides. Preferably, the polypeptide has been substantially purified to represent at least 75%, more preferably 85%, most preferably 95% of the total protein present in a preparation. In preferred embodiments, the purified polypeptide has at least 12 contiguous, at least 18 contiguous, at least 54 contiguous, or the entire amino acid sequence of SEQ. ID. NO. 4.

Another aspect of the present invention features a GABA_BR2-binding agent comprising a molecule which binds to a polypeptide consisting of the amino acid sequence of SEQ. ID. NO. 4. The binding agent is preferably a purified antibody. Other examples of binding agents include organic compounds which bind to GABA_BR2.

By "purified" in reference to a binding agent, such as an antibody, is meant that the binding agent is in a form (i.e., its association with other molecules) distinct from a naturally occurring binding agent, if the binding agent is found in nature. Preferably, the binding agent is an antibody provided as a purified preparation representing at least 1%, more preferably at least 50%, more preferably at least 85%, most preferably at least 95% of the total protein in the preparation.

Another aspect of the present invention describes a method of making a GABA_BR2 or a fragment thereof. The method is carried out by incubating recombinant cells containing nucleic acid encoding GABA_BR2 or a fragment thereof under conditions where the nucleic acid is expressed.

Another aspect of the present invention describes a method of selecting for compounds able to modulate GABA_BR activity. The method comprises the steps of (a) contacting a recombinant cell functionally expressing GABA_BR2 with a first test compound; and (b) measuring the ability of said test compound to affect GABA_BR activity. Compounds modulating GABA_BR activity either evoke a GABA_BR activity, potentiate GABA_BR activity, or inhibit a GABA_BR activity. Cells functionally expressing GABA_BR2 also express GABA_BR1a and/or GABA_BR1b.

Preferably, the ability of a plurality of different test compounds to affect GABA_BR activity are tested. In preferred

embodiments at least 5, at least 10, at least 50 different compounds, and at least 100 different compounds are tested over a span of one week.

Other aspects of the present invention describe coexpression systems and the use of such systems to measure the activity at, or screen compounds active at, GABA_BR1a, GABA_BR1b, or GABA_BR2, preferably GABA_BR2. The coexpression systems comprise at least one of GABA_BR1a and GABA_BR1b, GABA_BR2, and Gqo5.

Other aspects of the present invention describe coexpression systems and the use of such systems to measure the activity at, or screen compounds active at, GABA_BR1a, GABA_BR1b, or GABA_BR2. The coexpression systems comprise at least one of GABA_BR1a or GABA_BR1b, coexpressed with GABA_BR2 and Gqo5. The presence of Gqo5 provides for signal transduction swapping allowing for receptor activity to be measured by mobilization of intracellular calcium mediated by the activation of phospholipase C.

Assays using the coexpression systems described above can be used to screen chemical libraries for compounds that modulate GABA_B receptors. For example, in different embodiments, a library of compounds containing 10 or more compounds is screened at once; and 10 or more compounds are individually tested over the course of eight hours.

Preferably, the coexpression system is present in an isolated cell. An "isolated cell" includes tissue cells and refers to a cell present in a different environment (including a different concentration), than it is normally found in nature.

In other aspects, the invention describes transgenic nonhuman mammals containing a transgene encoding GABA_BR2, a GABA_BR2 fragment, or a derivative thereof; or a gene affecting the expression of GABA_BR2; and methods of creating a transgenic nonhuman mammal containing a transgene encoding an GABA_BR2, a GABA_BR2 fragment, or a derivative thereof.

Various examples are described herein. These examples are not intended in any way to limit the claimed invention.

Other features and advantages of the invention will be apparent from the following drawing, the description of the invention, the examples, and the claims.

BRIEF DESCRIPTION OF DRAWINGS

Figures 1a-1n illustrate the nucleic acid sequences encoding for the human GABA_BR2 designated SEQ. ID. NO. 1, human GABA_BR1a designated SEQ. ID. NO. 2, and human GABA_BR1b designated SEQ. ID. NO. 3.

Figures 2a-2f illustrate the amino acid sequences of the human GABA_BR2 (SEQ. ID. NO. 4); the rat GABA_BR1a (SEQ. ID. NO. 5); the rat GABA_BR1b protein (SEQ. ID. NO. 6); the human GABA_BR1a (SEQ. ID. NO. 7); and the human GABA_BR1a (SEQ. ID. NO. 8).

Figures 3a-3d provides the human calcium receptor nucleic acid sequence and the encoded for amino acid sequence.

Figure 4 illustrates functional expression of GABA_BR2 in *Xenopus* oocytes.

DETAILED DESCRIPTION OF THE INVENTION

The present invention features GABA_BR2. GABA_BR2 is closely related to GABA_BR1a and GABA_BR1b. Nucleic acid encoding for human GABA_BR2 has a sequence similarity of about 50% with nucleic acid encoding rat GABA_BR1a and rat GABA_BR1b. Human GABA_BR2 has a sequence identity of about 40% with rat GABA_BR1a and GABA_BR1b amino acid sequence.

Nucleic acid encoding GABA_BR2 was cloned by first identifying a human nucleic acid sequence approximately 38% identical to the nucleic acid sequence of rat GABA_BR1. Exact match polymerase chain reaction (PCR) primers were designed based on sequences from the identified sequence and used to amplify human GABA_BR2 nucleic acid from a human cerebral cortex cDNA library. A PCR product encoding human GABA_BR2 was isolated and cloned.

Northern blot analysis revealed that an approximately 6.3 Kb human GABA_BR2 transcript was abundantly expressed in the human brain. Expression was not detected in the heart, placenta, lung, liver, skeletal muscle, kidney or pancreas under conditions where GABA_BR2 transcript was identified in the human brain. Within the human brain GABA_BR2 is broadly expressed at variable levels:

Compounds modulating GABA_BR activity can be obtained, for example, by screening a group, or library, of compounds to identify those compounds having the desired activity and then synthesizing such compounds. Thus, included in the present

invention is a method of making a GABA_BR active compound by first screening for a compound having desired properties and then chemically synthesizing that compound.

5 Nucleic Acid Encoding GABA_BR2

 Nucleic acids encoding GABA_BR2 have a variety of different uses including one or more of the following: (1) producing receptor proteins which can be used, for example, for structure determination, to assay a molecule's activity on a receptor, and
10 to obtain GABA_BR2 modulatory agents; (2) being sequenced to determine a receptor's nucleotide sequence which can be used, for example, as a basis for comparison with other receptors to determine conserved regions, determine unique nucleotide
15 nucleotide sequences to be used as target sites for antisense nucleic acids, ribozymes, hybridization detection probes, or PCR amplification primers; (3) as hybridization detection probes to detect the presence of a native receptor and/or a related
20 nucleic acid sequence regions, for example, to generate regions to be probed by hybridization detection probes; and (5) to provide an extracellular domain, transmembrane domain, or extracellular domain for use in the construction of a chimeric receptor.

25 Hybridization probes and primers based on the GABA_BR2 sequence information provided herein can be used, for example, to obtain nucleic acid from different sources or to identify the presence of GABA_BR2 nucleic acid in a sample. Nucleic acid encoding proteins related to human GABA_BR2 can be obtained from
30 human and nonhuman sources. Such related nucleic acids are useful for identifying important GABA_BR2 structural motifs and may also provide new therapeutic target sites.

 Primer hybridization specificity to target nucleic acid can be adjusted by varying the hybridization conditions. When
35 annealing at higher stringency conditions of 50-60°C, sequences which are greater than about 75% complementarity to the primer will be amplified. By employing lower stringency conditions, annealing at 35-37°C, sequences which are greater than about 40-50% complementarity to the primer will be amplified.

Hybridization assay probes can be designed to detect the presence of a particular nucleic acid target sequence perfectly complementary to the probe and target sequences of lesser complementarity by varying the hybridization conditions and probe design. Factors affecting probe design, such as length, G and C content, possible self-complementarity, and wash conditions, are well known in the art. (See, for example, Sambrook et al., *Molecular Cloning*, Cold Spring Harbor Laboratory Press (1989).) Sambrook et al., *Molecular Cloning*, also discusses the design and use of degenerative probes based on polypeptide sequence information.

Preferably, the nucleic acid probes targeted to GABA_BR2 nucleic acid distinguish GABA_BR2 nucleic acid from GABA_B1a and GABA_B1b nucleic acid. Such probes are readily designed by comparing the nucleic acid sequences of target GABA_BR2, and non-target GABA_B1a and GABA_B1b, to obtain probes having proper probe:target and probe:non-target T_m characteristics. Preferably, the probe:target duplex T_m is at least about 5°C greater than the probe:non-target T_m.

Probes specific for a target contain a target complementary region and may also contain target non-complementary regions. The target non-complementary regions, if present, are designed not to affect the specificity of the probe. An example of a target non-complementary region is a nucleic acid sequence used as a capture sequence in a sandwich assay, where the capture sequence does not hybridize to target or non-target nucleic acids. (See, Stabinsky, U.S. Patent No. 4,739,044, and Ranki et al., U.S. Patent No. 4,563,419, both of which are incorporated by reference herein.)

The probes can be used under conditions of proper stringency conditions where target and non-target nucleic acid are distinguished. As the stringency conditions are increased, the complementarity of two nucleic acids required to form a stable duplex is also increased.

As a general guideline, high stringency conditions (e.g., hybridization at 50-65°C, 5X SSPC, 50% formamide, wash at 50-65°C, 0.5X SSPC) can be used to obtain hybridization between nucleic acid sequences having regions which are greater than about 90% complementary. Low stringency conditions (e.g., hybridization at

35-37°C, 5X SSPC, 40-45% formamide, wash at 42°C 1X SSPC) can be used so that sequences having regions greater than 35-45% complementarity will hybridize to the probe.

If desired, nucleic acid probes may be labeled with a detectable label using techniques well known in the art. Examples of detectable labels include radiolabels, enzymes, fluorescent molecules, and chemiluminescent molecules.

Any tissue can be used as a source for genomic DNA. However, with respect to RNA, the most preferred source is tissues which express elevated levels of GABA_BR2 or related proteins.

Specific nucleic acids can also be produced enzymatically using a host transformed with a plasmid encoding for the desired nucleic acid. Additionally, standard techniques for chemically synthesizing nucleic acids include solid phase phosphoramidite chemical synthesis.

GABA_BR2 polypeptides

GABA_BR2 polypeptides made up of GABA_BR2, GABA_BR2 fragments, and derivatives thereof have different uses including, being used to produce antibodies to determine the presence of the protein, and being used to screen for compounds able to bind to the protein. GABA_BR2 polypeptides are preferably produced using recombinant nucleic acid techniques.

Polypeptides can also be synthesized using solid phase techniques. Solid-phase synthesis is commenced from the carboxy-terminal end of the peptide using an α -amino protected amino acid. BOC protective groups can be used for all amino groups even though other protective groups are suitable. For example, BOC-lys-OH can be esterified to chloromethylated polystyrene resin supports. The polystyrene resin support is preferably a copolymer of styrene with about 0.5 to 2% divinylbenzene as a cross-linking agent which causes the polystyrene polymer to be completely insoluble in certain organic solvents. See Stewart et al., Solid-Phase Peptide Synthesis (1969), W.H. Freeman Co., San Francisco; and Merrifield, *J. Am. Chem. Soc.* 85:2149-2154, 1963. These and other methods of peptide synthesis are also exemplified by U.S. Patent Nos. 3,862,925; 3,842,067; 3,972,859; and 4,105,602.

GABA_BR2 derivatives, and nucleic acid encoding for GABA_BR2 derivatives can be produced using techniques well known in the art based upon the present disclosure. GABA_BR2 derivatives have a sequence similarity of at least 70%, more preferably at least 90%, even more preferably at least 95% sequence similarity to the amino acid sequence provided in SEQ. ID. NO. 4. Sequence similarity is preferably determined using BLASTN (Altschul et al., *J. Mol. Biol.* 215:403-410, 1990.)

Examples of specific types of derivatives include amino acid alterations such as deletions, substitutions, additions, and amino acid modifications. A "deletion" refers to the absence of one or more amino acid residue(s) in the related polypeptide. An "addition" refers to the presence of one or more amino acid residue(s) in the related polypeptide. Additions and deletions to a polypeptide may be at the amino terminus, the carboxy terminus, and/or internal. Amino acid "modification" refers to the alteration of a naturally occurring amino acid to produce a non-naturally occurring amino acid. A "substitution" refers to the replacement of one or more amino acid residue(s) by another amino acid residue(s) in the polypeptide. Derivatives can contain different combinations of alterations including more than one alteration and different types of alterations.

While the effect of an amino acid change varies depending upon factors such as phosphorylation, glycosylation, intra-chain linkages, tertiary structure, and the role of the amino acid in the active site or a possible allosteric site, it is generally preferred that the substituted amino acid is from the same group as the amino acid being replaced. To some extent the following groups contain amino acids which are interchangeable: the basic amino acids lysine, arginine, and histidine; the acidic amino acids aspartic and glutamic acids; the neutral polar amino acids serine, threonine, cysteine, glutamine, asparagine and, to a lesser extent, methionine; the nonpolar aliphatic amino acids glycine, alanine, valine, isoleucine, and leucine (however, because of size, glycine and alanine are more closely related and valine, isoleucine and leucine are more closely related); and the aromatic amino acids phenylalanine, tryptophan, and tyrosine. In addition, although classified in different categories, alanine, glycine, and serine seem to be interchangeable to some extent,

and cysteine additionally fits into this group, or may be classified with the polar neutral amino acids.

While proline is a nonpolar neutral amino acid, its replacement represents difficulties because of its effects on conformation. Thus, substitutions by or for proline are not preferred, except when the same or similar conformational results can be obtained. The conformation conferring properties of proline residues may be obtained if one or more of these is substituted by hydroxyproline (Hyp).

Examples of modified amino acids include the following: altered neutral nonpolar amino acids such as ω -amino acids of the formula $H_2N(CH_2)_nCOOH$ where n is 2-6, sarcosine (Sar), t-butylalanine (t-BuAla), t-butylglycine (t-BuGly), N-methyl isoleucine (N-MeIle), and norleucine (Nleu); altered neutral aromatic amino acids such as phenylglycine; altered polar, but neutral amino acids such as citrulline (Cit) and methionine sulfoxide (MSO); altered neutral and nonpolar amino acids such as cyclohexyl alanine (Cha); altered acidic amino acids such as cysteic acid (Cya); and altered basic amino acids such as ornithine (Orn).

Preferred derivatives have one or more amino acid alteration(s) which do not significantly affect the receptor activity of the related receptor protein. In regions of the $GABA_B R2$ not necessary for receptor activity amino acids may be deleted, added or substituted with less risk of affecting activity. In regions required for receptor activity, amino acid alterations are less preferred as there is a greater risk of affecting receptor activity. Such alterations should be conservative alterations. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity which acts as a functional equivalent.

Conserved regions tend to be more important for protein activity than non-conserved regions. Standard procedures can be used to determine the conserved and non-conserved regions important of receptor activity using *in vitro* mutagenesis techniques or deletion analyses and measuring receptor activity as described by the present disclosure.

Derivatives can be produced using standard chemical techniques and recombinant nucleic acid techniques.

Modifications to a specific polypeptide may be deliberate, as through site-directed mutagenesis and amino acid substitution during solid-phase synthesis, or may be accidental such as through mutations in hosts which produce the polypeptide.

- 5 Polypeptides including derivatives can be obtained using standard techniques such as those described by Sambrook et al., *Molecular Cloning*, Cold Spring Harbor Laboratory Press (1989). For example, Chapter 15 of Sambrook describes procedures for site-directed mutagenesis of cloned DNA.

10

GABA_BR2 Antibodies

- Antibodies binding GABA_BR2 have various uses such as being used as therapeutic agents to modulate GABA_BR activity; as diagnostic tools for determining GABA_BR2 number; as research tools
15 for studying receptor synthesis, structure, and function; and as a tool by purifying GABA_BR2.

- GABA_BR2, and GABA_BR2 fragments retaining antigenic determinants, can be used to generate antibodies recognizing GABA_BR2. Preferably, polypeptide fragments used to generate
20 antibodies are at least six amino acid in length. Both polyclonal and monoclonal antibodies can be generated.

- Antibodies can be produced using standard techniques such as those described by Harlow and Lane in *Antibodies, a Laboratory Manual*, Cold Spring Harbor Laboratory, 1988. Sources of
25 immunogens for antibody production include purified GABA_BR2, GABA_BR2 fragments, and whole cells expressing GABA_BR2. The present invention also includes hybridoma cells secreting monoclonal antibodies to GABA_BR2.

30 Recombinant Cells

- Nucleic acid expressing a functional GABA_BR2 can be used to create transfected cells lines functionally expressing GABA_BR2. Such cell lines have a variety of uses such as being used for high-throughput screening for compounds modulating GABA_BR
35 activity; being used to assay binding to GABA_BR2; and as factories to produce large amounts of GABA_BR2, or GABA_BR2 fragments.

A variety of cell lines can couple exogenously expressed receptors to endogenous functional responses. Cell lines such as NIH-3T3, HeLa, NG115, CHO, HEK 293 and COS7 which are expected to

lack GABA_BR2 can be tested to confirm that they lack an endogenous GABA_BR2.

Production of stable transfectants can be accomplished by transfection of an appropriate cell line with an expression vector, such as the eukaryotic pMSG vectors. Expression vectors containing a promoter region, such as the mouse mammary tumor virus promoter (MMTV), drive high-level transcription of cDNAs in a variety of mammalian cells. In addition, these vectors contain genes for selecting cells stably expressing cDNA of interest. The selectable marker in the pMSG vectors encodes an enzyme, xanthine-guanine phosphoribosyl transferase (XGPRT), conferring resistance to a metabolic inhibitor that is added to the culture to kill nontransfected cells.

The most effective method for transfection of eukaryotic cell lines with plasmid DNA varies with the given cell type. The GABA_BR2 expression construct will be introduced into cultured cells by the appropriate technique, such as Ca²⁺ phosphate precipitation, DEAE-dextran transfection, lipofection or electroporation. Expression of the GABA_BR2 cDNA in cell lines can be assessed by solution hybridization and Northern blot analysis.

Assaying For Compounds Modulating GABA_BR Activity

The ability of compounds to modulate GABA_BR activity can be assayed by measuring alterations of cellular processes affected by GABA_BR activity. Generally, a GABA_BR2 agonist is present when measuring antagonist activity. However, protein fusions can be created, for example, where an agonist extracellular binding domain of GABA_BR2 is swapped with the agonist binding domain of a different receptor allowing for the measurement of antagonist activity using an agonist of the different receptor; or where the intracellular domain of GABA_BR2 is swapped with the intracellular domain of a different receptor allowing for the measuring of GABA_BR activity by measuring intracellular effects caused by the different receptor.

Chimeric proteins are preferably produced using recombinant nucleic acid techniques to provide an appropriate nucleic acid encoding for the chimeric protein. Preferably, portions of GABA_BR2 are swapped with portions of the calcium receptor. The GABA_BR2 extracellular domain is made up of approximately amino

acids 1-422 Of SEQ. ID. NO. 4, the GABA_BR2 transmembrane domain is made up of approximately amino acids 423-686 Of SEQ. ID. NO. 4, and the GABA_BR2 intracellular domain is made up of approximately amino acids 687-883 Of SEQ. ID. NO. 4. The human calcium
5 receptor amino acid and encoding nucleic acid is provided in Figure 3. The calcium receptor extracellular domain is made up of approximately amino acids 1-612, the calcium receptor transmembrane domain is made up of approximately amino acids 613-862, and the calcium receptor intracellular domain is made up of
10 approximately amino acids 863-1078. Calcium receptor activity can be measured using techniques well known in the art such as those described by Brown et al., U.S. Patent No. 5,688,938, hereby incorporated by reference herein.

15 Binding Assays

The present invention also includes using GABA_BR2 and fragments thereof in binding assays. Binding assays can be carried out using techniques well known in the art. Binding assays preferably employ radiolabeled binding agents.

20 An example of a binding assay is carried out by first attaching GABA_BR2, or a fragment thereof, to a solid-phase support to create an affinity matrix. The affinity matrix is then contacted with potential GABA_BR2 binding agents. A large library of compounds may be used to determine those compounds binding to
25 the affinity matrix. Bound compounds can be eluted from the column.

Transgenic Animals

The present invention also concerns the construction and use
30 of transgenic animals, and transformed cells, encoding GABA_BR2. Transgenic nonhuman mammals are particularly useful as an *in vivo* test system for studying the effects of introducing GABA_BR2; regulating the expression of GABA_BR2 (e.g., through the introduction of additional genes, antisense nucleic acids, or
35 ribozymes); and studying the effect of compounds which mimic or block the effect of GABA_BR2.

Experimental model systems for studying the physiological role of the GABA_BR2 can be created having varying degrees of

receptor expression. For example, nucleic acid encoding a receptor may be inserted into cells naturally expressing the receptor such that the gene is expressed at much higher levels. Alternatively, a recombinant gene may be used to inactivate the endogenous gene by homologous recombination and, thereby, create an GABA_BR2 deficient cell, tissue, or animal.

Inactivation of a gene can be caused, for example, by using a recombinant gene engineered to contain an insertional mutation (e.g., the *neo* gene). The recombinant gene is inserted into the genome of a recipient cell, tissue or animal, and inactivates transcription of the receptor. Such a construct may be introduced into a cell, such as an embryonic stem cell, by techniques such as transfection, transduction, and injection. Stem cells lacking an intact receptor sequence may generate transgenic animals deficient in the receptor.

Preferred test models are transgenic animals. A transgenic animal has cells containing DNA which has been artificially inserted into a cell and inserted into the genome of the animal which develops from that cell. Preferred transgenic animals are primates, mice, rats, cows, pigs, horses, goats, sheep, dogs and cats.

A variety of methods are available for producing transgenic animals. For example, DNA can be injected into the pronucleus of a fertilized egg before fusion of the male and female pronuclei, or injected into the nucleus of an embryonic cell (e.g., the nucleus of a two-cell embryo) following the initiation of cell division (Brinster et al., *Proc. Nat. Acad. Sci. USA* 82: 4438-4442, 1985). By way of another example, embryos can be infected with viruses, especially retroviruses, modified to carry GABA_BR2 nucleotide sequences.

Pluripotent stem cells derived from the inner cell mass of the embryo and stabilized in culture can be manipulated in culture to incorporate nucleotide sequences of the invention. A transgenic animal can be produced from such stem cells through implantation into a blastocyst that is implanted into a foster mother and allowed to come to term. Animals suitable for transgenic experiments can be obtained from standard commercial sources such as Charles River (Wilmington, MA), Taconic (Germantown, NY), and Harlan Sprague Dawley (Indianapolis, IN).

Methods for the culturing of embryonic stem (ES) cells and the subsequent production of transgenic animals by the introduction of DNA into ES cells using methods such as electroporation, calcium phosphate/DNA precipitation and direct injection are well known to those of ordinary skill in the art. See, for example, Teratocarcinomas and Embryonic Stem Cells, A Practical Approach, E.J. Robertson, ed., IRL Press (1987).

Procedures for embryo manipulations are well known in the art. Procedures for manipulating rodent embryo and for microinjecting DNA into the pronucleus of the zygote are well known in the art. Microinjection procedures for fish, amphibian eggs and birds are well known in the art and are described, for example, in Houdebine and Chourrout, *Experientia* 47: 897-905, 1991. Procedures for introducing DNA into tissues of animals are well known in the art and are described, for example, in U.S. Patent No. 4,945,050.

Transfection and isolation of desired clones can be carried out using standard techniques (e.g., E.J. Robertson, *supra*). For example, random gene integration can be carried out by co-transfecting nucleic acid with a gene encoding antibiotic resistance. Alternatively, for example, the gene encoding antibiotic resistance is physically linked to a nucleic acid sequence encoding GABA_AR2.

DNA molecules introduced into ES cells can also be integrated into the chromosome through the process of homologous recombination. (E.g., Capecchi, *Science* 244: 1288-1292, 1989.) Methods for positive selection of the recombination event (e.g., neomycin resistance) and dual positive-negative selection (e.g., neomycin resistance and gancyclovir resistance) and the subsequent identification of the desired clones by PCR have been described in references such as Capecchi, *supra* and Joyner et al., *Nature* 338:153-156, 1989, which is hereby incorporated by reference herein.

The final phase of the procedure is to inject targeted ES cells into blastocysts and to transfer the blastocysts into pseudopregnant females. The resulting chimeric animals are bred and the offspring are analyzed by Southern blotting to identify individuals carrying the transgene.

An example describing the preparation of a transgenic mouse

is as follows. Female mice are induced to superovulate and placed with males. The mated females are sacrificed by CO₂ asphyxiation or cervical dislocation and embryos are recovered from excised oviducts. Surrounding cumulus cells are removed.
5 Pronuclear embryos are then washed and stored until the time of injection.

Randomly cycling adult female mice paired with vasectomized males serve as recipients for implanted embryos. Recipient females are mated at the same time as donor females and embryos
10 are transferred surgically to recipient females.

Procedures for generating transgenic rats are similar to that of mice. (E.g., Hammer et al., Cell 63:1099-1112, 1990.) Procedures for producing transgenic non-rodent mammals and other animals are well known in art. (E.g., Houdebine and Chourrout,
15 *supra*; Pursel et al., Science 244:1281-1288, 1989; and Simms et al., Bio/Technology 6:179-183, 1988.)

Therapeutic Modulation

Different types of diseases and disorders can be treated
20 using compounds modulating GABA_BR activity. Additionally, such compounds can be used prophylactically. Compounds modulating GABA_BR activity can be administered to patients who would benefit from such treatment. Patients are mammals, preferably humans.

Modulating GABA_BR activity can be carried to achieve useful
25 therapeutic effects such as preventing or treating one or more of the following: spasticity and motor control disorders using GABA_BR agonists; pain, using GABA_BR antagonists; cognitive disorders using GABA_BR antagonists; neurological disorders such as Alzheimer's disease and Huntington's disease; psychiatric
30 disorders, such as depression using GABA_BR agonists; alcohol dependence and withdrawal using GABA_BR antagonists; feeding behavior; cardiovascular and respiratory disorders with antagonists exerting an excitatory effect and agonists depressing inspiratory neurons; and peripheral function disorders.

35 Modulators of GABA_BR activity can be administered to a patient using standard techniques. Techniques and formulations generally may be found in Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Co., Easton, PA, 1990 (hereby incorporated by reference herein).

Suitable dosage forms, in part, depend upon the use or the route of entry, for example, oral, transdermal, transmucosal, or by injection (parenteral). Such dosage forms should allow the therapeutic agent to reach a target cell whether the target cell is present in a multicellular host or in culture. For example, pharmacological compounds or compositions injected into the blood stream should be soluble. Other factors are well known in the art, and include considerations such as toxicity and dosage forms which retard the therapeutic agent from exerting its effect.

Therapeutic compounds can be formulated as pharmaceutically acceptable salts and complexes thereof. Pharmaceutically acceptable salts are non-toxic salts in the amounts and concentrations at which they are administered. The preparation of such salts can facilitate the pharmacological use by altering the physical characteristics of the compound without preventing it from exerting its physiological effect. Useful alterations in physical properties include lowering the melting point to facilitate transmucosal administration and increasing the solubility to facilitate administering higher concentrations of the drug.

The pharmaceutically acceptable salt of a compound may be present as a complex. Examples of complexes include an 8-chlorotheophylline complex (analogous to, e.g., dimenhydrinate:diphenhydramine 8-chlorotheophylline (1:1) complex; Dramamine) and various cyclodextrin inclusion complexes.

Pharmaceutically acceptable salts include acid addition salts such as those containing sulfate, hydrochloride, fumarate, maleate, phosphate, sulfamate, acetate, citrate, lactate, tartrate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, cyclohexylsulfamate and quinate.

Pharmaceutically acceptable salts can be obtained from acids such as hydrochloric acid, maleic acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, fumaric acid, and quinic acid.

Pharmaceutically acceptable salts also include basic addition salts such as those containing benzathine, chlorprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine,

aluminum, calcium, lithium, magnesium, potassium, sodium, ammonium, alkylamine, and zinc, when acidic functional groups, such as carboxylic acid or phenol are present. For example, see Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Co., Easton, PA, p. 1445, 1990. Such salts can be prepared using the appropriate corresponding bases.

Carriers or excipients can also be used to facilitate administration of therapeutic agents. Examples of carriers include calcium carbonate, calcium phosphate, various sugars such as lactose, glucose, or sucrose, or types of starch, cellulose derivatives, gelatin, vegetable oils, polyethylene glycols and physiologically compatible solvents. Examples of physiologically compatible solvents include sterile solutions of water for injection (WFI), saline solution and dextrose.

GABA_BR modulating compounds can be administered by different routes including intravenous, intraperitoneal, subcutaneous, intramuscular, oral, topical (transdermal), or transmucosal administration. For systemic administration, oral administration is preferred. For oral administration, for example, the compounds can be formulated into conventional oral dosage forms such as capsules, tablets, and liquid preparations such as syrups, elixirs, and concentrated drops.

Alternatively, injection (parenteral administration) may be used, e.g., intramuscular, intravenous, intraperitoneal, and subcutaneous. For injection, compounds are formulated in liquid solutions, preferably, in physiologically compatible buffers or solutions, such as saline solution, Hank's solution, or Ringer's solution. In addition, the compounds may be formulated in solid form and redissolved or suspended immediately prior to use. Lyophilized forms can also be produced.

Systemic administration can be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are well known in the art, and include, for example, for transmucosal administration, bile salts and fusidic acid derivatives. In addition, detergents may be used to facilitate permeation. Transmucosal administration, for example, may be through nasal sprays, rectal suppositories, or vaginal suppositories.

For topical administration, compounds can be formulated into ointments, salves, gels, or creams, as is well known in the art.

The amounts of various GABA_BR modulating compounds to be administered can be determined by standard procedures taking into account factors such as the compound IC₅₀, EC₅₀, the biological half-life of the compound, the age, size and weight of the patient, and the disease or disorder associated with the patient. The importance of these and other factors to be considered are well known to those of ordinary skill in the art. Generally, the amount is expected to preferably be between about 0.01 and 50 mg/kg of the animal to be treated.

EXAMPLES

The example provided below illustrates different aspects and embodiments of the present invention. The example is not intended to limit the claimed invention.

Functional expression of GABA_BR2

Xenopus oocytes were co-injected with *in vitro* transcribed RNA (7 ng) encoding GABA_BR1a, GABA_BR2 and chimeric Gqo5. Chimeric Gqo5 is described in *Nature* 363:274-276, 1993. Coexpression of the different proteins was employed because GABA_BR functions as a heterodimer of the subunits GABA_BR1 or GABA_BR2 (Jones et al. *Nature* 396:674-679, 1998). Following a 72 hour incubation, the oocytes were voltage clamped using standard electrophysiological techniques (Hille, B., Ionic Channels of Excitable membranes, pp. 30-33, Sinauer Associates, Inc., Sunderland, MA, 1992). Activation of the receptor heterodimers was detected by increases in the calcium-activated chloride current.

Application of the GABA_B receptor agonist baclofen caused dose-dependent, reversible, oscillatory increases in the calcium-activated chloride current as shown in Figure 4, with an EC₅₀ of approximately 1 μ M. These responses were completely blocked by the competitive GABA_B receptor antagonist SCH 50911 (100 μ M). Oocytes expressing GABA_B receptor heterodimers with the inwardly rectifying potassium channels (GIRKS; Kir3.1/3.2/3.4) were used as the positive control (Jones et al., *Nature* 396:674-679, 1998.) Thus, the use of the chimeric G-Protein Gqo5 promotes signal transduction through mobilization of intracellular calcium.

Other embodiments are within the following claims. Thus, while several embodiments have been shown and described, various modifications may be made, without departing from the spirit and
5 scope of the present invention.

Claims

1. A purified nucleic acid comprising at least 18 contiguous nucleotides of a nucleic acid sequence provided in SEQ ID NO: 1.
5
2. The purified nucleic acid of claim 1, comprising at least 27 contiguous nucleotides of the nucleic acid sequence provided in SEQ ID NO: 1.
10
3. The purified nucleic acid of claim 2, comprising at least 45 contiguous nucleotides of the nucleic acid sequence provided in SEQ ID NO: 1.
4. The purified nucleic acid of claim 3, comprising the nucleic acid sequence provided in SEQ ID NO: 1.
15
5. A purified nucleic acid comprising a nucleic acid sequence encoding at least 6 contiguous amino acids of an amino acid sequence provided in SEQ. ID. NO: 4.
20
6. The purified nucleic acid of claim 5, wherein said nucleic acid encodes at least 12 contiguous amino acids of the amino acid sequence provided in SEQ. ID. NO: 4.
25
7. The purified nucleic acid of claim 6, wherein said nucleic acid encodes at least 18 contiguous amino acids of the amino acid sequence provided in SEQ. ID. NO: 4.
8. The purified nucleic acid of claim 7, wherein said nucleic acid encodes at least 54 contiguous amino acids of the amino acid sequence provided in SEQ. ID. NO: 4.
30
9. The purified nucleic acid of claim 8, wherein said nucleic acid encodes the amino acid sequence provided in SEQ. ID. NO: 4.
35
10. The purified nucleic acid of any of claims 1-9, wherein said nucleic acid is substantially purified.

11. The purified nucleic acid of any of claims 1-9, wherein said nucleic acid is recombinant nucleic acid which is part of an expression vector.

5

12. The purified nucleic acid of any of claims 1-9, wherein said nucleic acid is transcriptionally coupled to an exogenous promoter.

10

13. A recombinant cell comprising the expression vector of claim 11.

15

14. A recombinant cell made by a process comprising the step of introducing the nucleic acid of any one of claims 1-12 into a cell.

20

15. A purified nucleic acid comprising a nucleotide sequence of 20 contiguous nucleotides of which at least 18 nucleotides are complementary to the nucleic acid sequence provided in SEQ ID NO: 1 or the perfect complement of SEQ ID NO: 1.

25

16. The nucleic acid of claim 15, wherein said purified nucleic acid comprises a nucleotide sequence of 20 contiguous nucleotides which has at least 19 bases complementary to the nucleic acid sequence provided in SEQ ID NO: 1 or the perfect complement of SEQ ID NO: 1.

30

17. The nucleic acid of claim 16, wherein said purified nucleic acid comprises a nucleotide sequence of 20 contiguous nucleotides which is complementary to the nucleic acid sequence provided in SEQ ID NO: 1 or the perfect complement of SEQ ID NO: 1.

35

18. A purified polypeptide comprising at least 6 contiguous amino acids of an amino acid sequence provided in SEQ. ID. NO: 4.

19. The purified polypeptide of claim 18, comprising at least 12 contiguous amino acids of the amino acid sequence

provided in SEQ. ID. NO: 4.

20. The purified polypeptide of claim 19, comprising at least 18 contiguous amino acids of the amino acid sequence provided in SEQ. ID. NO: 4.

21. The purified polypeptide of claim 20, comprising at least 54 contiguous amino acids of the amino acid sequence provided in SEQ. ID. NO: 4.

22. The purified polypeptide of claim 21, consisting of the amino acid sequence provided in SEQ. ID. NO: 4.

23. The polypeptide of any one of claims 18-22, wherein said polypeptide is substantially purified.

24. A purified GABA_BR2-binding agent comprising a molecule which binds to a polypeptide consisting of the amino acid sequence of SEQ. ID. NO: 4.

25. The binding agent of claim 24, wherein said binding agent is an antibody.

26. A method of making a GABA_BR2 or fragment thereof comprising the step of incubating the recombinant cells of claim 13 under conditions wherein the nucleic acid encoding for the GABA_BR2 is expressed.

27. The method of claim 26, further comprising the step of purifying said GABA_BR2 or fragment thereof.

28. A method of selecting for a compound modulating GABA_BR activity comprising the steps of

- a) contacting a recombinant cell functionally expressing GABA_BR2 with a first test compound; and
- b) measuring the ability of said test compound to affect GABA_BR activity to select for said compound modulating GABA_BR activity.

29. The method of claim 28, wherein the ability of a plurality of different test compounds to affect GABA_BR activity are tested to select for said compound modulating GABA_BR activity.

- 5 30. A coexpression system comprising
- a) a cell;
 - b) at least one of GABA_BR1a and GABA_BR1b, which is present
- in said cell;
- c) GABA_BR2, which is present in said cell; and
 - 10 d) Gqo5, which is present in said cell.

31. A method of screening for one or more compounds active at GABA_BR1a, GABA_BR1b, or GABA_BR2 comprising the steps of
- 15 contacting the coexpression system of claim 30 with at least one of said compounds and measuring the ability of said compounds to effect the mobilization of intracellular calcium.

32. The method of claim 31, wherein 10 or more compounds are individually tested for their ability to effect the
- 20 mobilization of intracellular calcium over the course of 8 hours.

33. A transgenic nonhuman mammal comprising a nonhuman mammal and a recombinant nucleic acid encoding a polypeptide comprising 6 contiguous amino acids of an amino acid sequence
- 25 provided in SEQ. ID. NO: 4.

ClustalW Formatted Alignments

```
SEQ. ID. NO.1  A T G G C T T C C C G C G G A G C T C C G G G C
SEQ. ID. NO. 2  A T G T T G C T G C T G C T G C T A C T G G C G C
SEQ. ID. NO. 3  A T G G G G C C C G G G G C C C C T T T T G C C C

SEQ. ID. NO.1  A G C C C G G G C C G C G C C G C C G C C G C C A
SEQ. ID. NO. 2  C A C T C T T C C T C C G C C C C C C G G G C G C
SEQ. ID. NO. 3  G G G T G G G G T G G C C A C T G C C G C T T C T

SEQ. ID. NO.1  C C G C C G C C C G C G C G C C T G C T A C T G C
SEQ. ID. NO. 2  G G G C G G G G C G C A G A C C C C C A A C G C C
SEQ. ID. NO. 3  G G T T G T G A T G G C G G C A G G G G T G G C T

SEQ. ID. NO.1  T A C T G C T G C T G C C G C T G C T G C T G C C
SEQ. ID. NO. 2  A C C T C A G A A G G T T G C C A G A T C A T A C
SEQ. ID. NO. 3  C C G G T G T G G G C C T C C C A C T C C C C C C

SEQ. ID. NO.1  T C T G G C G C C C G G G G C C T G G G G C T G G
SEQ. ID. NO. 2  A C C C G C C C C T G G G A A G G G G G C A T C A G
SEQ. ID. NO. 3  A T C T C C C G C G G C C T C A C T C G C G G G T

SEQ. ID. NO.1  G C G C G G G G C G C C C C C C G G C C G C C G C
SEQ. ID. NO. 2  G T A C C G G G G C C T G A C T C G G G A C C A G
SEQ. ID. NO. 3  C C C C C C G C A C C C C T C C T C A G A A C G G

SEQ. ID. NO.1  C C A G C A G C C C G C C G C T C T C C A T C A T
SEQ. ID. NO. 2  G T G A A G G C T A T C A A C T T C C T G C C A G
SEQ. ID. NO. 3  C G C G C A G T G T A C A T C G G G G C A C T G T

SEQ. ID. NO.1  G G G C C T C A T G C C G C T C A C C A A G G A G
SEQ. ID. NO. 2  T G G A C T A T G A G A T T G A G T A T G T G T G
SEQ. ID. NO. 3  T T C C C A T G A G C G G G G G C T G G C C A G G

SEQ. ID. NO.1  G T G G C C A A G G G C A G C A T C G G G C G C G
SEQ. ID. NO. 2  C C G G G G G G A G C G C G A G G T G G T G G G G
SEQ. ID. NO. 3  G G G C C A G G C C T G C C A G C C C G C G G T G
```

FIGURE 1A

SEQ. ID. NO.1 G T G T G C T C C C C G C C G T G G A A C T G G C
SEQ. ID. NO. 2 C C C A A G G T C C G C A A G T G C C T G G C C A
SEQ. ID. NO. 3 G A G A T G G C G C T G G A G G A C G T G A A T A

SEQ. ID. NO.1 C A T C G A G C A G A T C C G C A A C G A G T C A
SEQ. ID. NO. 2 A C G G C T C C T G G A C A G A T A T G G A C A C
SEQ. ID. NO. 3 G C C G C A G G G A C A T C C T G C C G G A C T A

SEQ. ID. NO.1 C T C C T G C G C C C C T A C T T C C T C G A C C
SEQ. ID. NO. 2 A C C C A G C C G C T G T G T C C G A A T C T G C
SEQ. ID. NO. 3 T G A G C T C A A G C T C A T C C A C C A C G A C

SEQ. ID. NO.1 T G C G G C T C T A T G A C A C G G A G T G C G A
SEQ. ID. NO. 2 T C C A A G T C T T A T T T G A C C C T G G A A A
SEQ. ID. NO. 3 A G C A A G T G T G A T C C A G G C C A A G C C A

SEQ. ID. NO.1 C A A C G C A A A A G G G T T G A A A G C C T T C
SEQ. ID. NO. 2 A T G G G A A G G T T T T C C T G A C G G G T G G
SEQ. ID. NO. 3 C C A A G T A C C T A T A T G A G C T G C T C T A

SEQ. ID. NO.1 T A C G A T G C A A T A A A A T A C G G G C C G A
SEQ. ID. NO. 2 G G A C C T C C C A G C T C T G G A C G G A G C C
SEQ. ID. NO. 3 C A A C G A C C C T A T C A A G A T C A T C C T T

SEQ. ID. NO.1 A C C A C T T G A T G G T G T T T G G A G G C G T
SEQ. ID. NO. 2 C G G G T G G A T T T C C G G T G T G A C C C C G
SEQ. ID. NO. 3 A T G C C T G G C T G C A G C T C T G T C T C C A

SEQ. ID. NO.1 C T G T C C A T C C G T C A C A T C C A T C A T T
SEQ. ID. NO. 2 A C T T C C A T C T G G T G G G C A G C T C C C G
SEQ. ID. NO. 3 C G C T G G T G G C T G A G G C T G C T A G G A T

SEQ. ID. NO.1 G C A G A G T C C C T C C A A G G C T G G A A T C
SEQ. ID. NO. 2 G A G C A T C T G T A G T C A G G G C C A G T G G
SEQ. ID. NO. 3 G T G G A A C C T C A T T G T G C T T T C C T A T

SEQ. ID. NO.1 T G G T G C A G C T T T C T T T T G C T G C A A C
SEQ. ID. NO. 2 A G C A C C C C C A A G C C C C A C T G C C A G G
SEQ. ID. NO. 3 G G C T C C A G C T C A C C A G C C C T G T C A A

FIGURE 1B

SEQ. ID. NO.1 C A C G C C T G T T C T A G C C G A T A A G A A A
SEQ. ID. NO.2 T G A A T C G A A C G C C A C A C T C A G A A C G
SEQ. ID. NO.3 A C C G G C A G C G T T T C C C C A C T T T C T T

SEQ. ID. NO.1 A A A T A C C C T T A T T T C T T T C G G A C C G
SEQ. ID. NO.2 G C G C G C A G T G T A C A T C G G G G C A C T G
SEQ. ID. NO.3 C C G A A C G C A C C C A T C A G C C A C A C T C

SEQ. ID. NO.1 T C C C A T C A G A C A A T G C G G T G A A T C C
SEQ. ID. NO.2 T T T C C C A T G A G C G G G G G C T G G C C A G
SEQ. ID. NO.3 C A C A A C C C T A C C C G C G T G A A A C T C T

SEQ. ID. NO.1 A G C C A T T C T G A A G T T G C T C A A G C A C
SEQ. ID. NO.2 G G G G C C A G G C C T G C C A G C C C G C G G T
SEQ. ID. NO.3 T T G A A A A G T G G G G C T G G A A G A A G A T

SEQ. ID. NO.1 T A C C A G T G G A A G C G C G T G G G C A C G C
SEQ. ID. NO.2 G G A G A T G G C G C T G G A G G A C G T G A A T
SEQ. ID. NO.3 T G C T A C C A T C C A G C A G A C C A C T G A G

SEQ. ID. NO.1 T G A C G C A A G A C G T T C A G A G G T T C T C
SEQ. ID. NO.2 A G C C G C A G G G A C A T C C T G C C G G A C T
SEQ. ID. NO.3 G T C T T C A C T T C G A C T C T G G A C G A C C

SEQ. ID. NO.1 T G A G G T G C G G A A T G A C C T G A C T G G A
SEQ. ID. NO.2 A T G A G C T C A A G C T C A T C C A C C A C G A
SEQ. ID. NO.3 T G G A G G A A C G A G T G A A G G A G G C T G G

SEQ. ID. NO.1 G T T C T G T A T G G C G A G G A C A T T G A G A
SEQ. ID. NO.2 C A G C A A G T G T G A T C C A G G C C A A G C C
SEQ. ID. NO.3 A A T T G A G A T T A C T T T T C C G C C A G A G T

SEQ. ID. NO.1 T T T C A G A C A C C G A G A G C T T C T C C A A
SEQ. ID. NO.2 A C C A A G T A C C T A T A T G A G C T G C T C T
SEQ. ID. NO.3 T T C T T C T C A G A T C C A G C T G T G C C C G

SEQ. ID. NO.1 C G A T C C C T G T A C C A G T G T C A A A A A G
SEQ. ID. NO.2 A C A A C G A C C C T A T C A A G A T C A T C C T
SEQ. ID. NO.3 T C A A A A A C C T G A A G C G C C A G G A T G C

FIGURE 1C

SEQ. ID. NO.1 C T G A A G G G G A A T G A T G T G C G G A T C A
SEQ. ID. NO. 2 T A T G C C T G G C T G C A G C T C T G T C T C C
SEQ. ID. NO. 3 C C G A A T C A T C G T G G G A C T T T T C T A T

SEQ. ID. NO.1 T C C T T G G C C A G T T T G A C C A G A A T A T
SEQ. ID. NO. 2 A C G C T G G T G G C T G A G G C T G C T A G G A
SEQ. ID. NO. 3 G A G A C T G A A G C C C G G A A A G T T T T T T

SEQ. ID. NO.1 G G C A G C A A A A G T G T T C T G T T G T G C A
SEQ. ID. NO. 2 T G T G G A A C C T C A T T G T G C T T T C C T A
SEQ. ID. NO. 3 G T G A G G T G T A C A A G G A G C G T C T C T T

SEQ. ID. NO.1 T A C G A G G A G A A C A T G T A T G G T A G T A
SEQ. ID. NO. 2 T G G C T C C A G C T C A C C A G C C C T G T C A
SEQ. ID. NO. 3 T G G G A A G A A G T A C G T C T G G T T C C T C

SEQ. ID. NO.1 A A T A T C A G T G G A T C A T T C C G G G C T G
SEQ. ID. NO. 2 A A C C G G C A G C G T T T C C C C A C T T T C T
SEQ. ID. NO. 3 A T T G G G T G G T A T G C T G A C A A T T G G T

SEQ. ID. NO.1 G T A C G A G C C T T C T T G G T G G G A G C A G
SEQ. ID. NO. 2 T C C G A A C G C A C C C A T C A G C C A C A C T
SEQ. ID. NO. 3 T C A A G A T C T A C G A C C C T T C T A T C A A

SEQ. ID. NO.1 G T G C A C A C G G A A G C C A A C T C A T C C C
SEQ. ID. NO. 2 C C A C A A C C C T A C C C G C G T G A A A C T C
SEQ. ID. NO. 3 C T G C A C A G T G G A T G A G A T G A C T G A G

SEQ. ID. NO.1 G C T G C C T C C G G A A G A A T C T G C T T G C
SEQ. ID. NO. 2 T T T G A A A A G T G G G G C T G G A A G A A G A
SEQ. ID. NO. 3 G C G G T G G A G G G C C A C A T C A C A A C T G

SEQ. ID. NO.1 T G C C A T G G A G G G C T A C A T T G G C G T G
SEQ. ID. NO. 2 T T G C T A C C A T C C A G C A G A C C A C T G A
SEQ. ID. NO. 3 A G A T T G T C A T G C T G A A T C C T G C C A A

SEQ. ID. NO.1 G A T T T C G A G C C C C T G A G C T C C A A G C
SEQ. ID. NO. 2 G G T C T T C A C T T C G A C T C T G G A C G A C
SEQ. ID. NO. 3 T A C C C G C A G C A T T T C C A A C A T G A C A

FIGURE 1D

SEQ. ID. NO.1 A G A T C A A G A C C A T C T C A G G A A A G A C
SEQ. ID. NO. 2 C T G G A G G A A C G A G T G A A G G A G G C T G
SEQ. ID. NO. 3 T C C C A G G A A T T T G T G G A G A A A C T A A

SEQ. ID. NO.1 T C C A C A G C A G T A T G A G A G A G A G T A C
SEQ. ID. NO. 2 G A A T T G A G A T T A C T T T C C G C C A G A G
SEQ. ID. NO. 3 C C A A G C G A C T G A A A A G A C A C C C T G A

SEQ. ID. NO.1 A A C A A C A A G C G G T C A G G C G T G G G G C
SEQ. ID. NO. 2 T T T C T T C T C A G A T C C A G C T G T G C C C
SEQ. ID. NO. 3 G G A G A C A G G A G G C T T C C A G G A G G C A

SEQ. ID. NO.1 C C A G C A A G T T C C A C G G G T A C G C C T A
SEQ. ID. NO. 2 G T C A A A A A C C T G A A G C G C C A G G A T G
SEQ. ID. NO. 3 C C G C T G G C C T A T G A T G C C A T C T G G G

SEQ. ID. NO.1 C G A T G G C A T C T G G G T C A T C G C C A A G
SEQ. ID. NO. 2 C C C G A A T C A T C G T G G G A C T T T T T C T A
SEQ. ID. NO. 3 C C T T G G C A C T G G C C C T G A A C A A G A C

SEQ. ID. NO.1 A C A C T G C A G A G G G C C A T G G A G A C A C
SEQ. ID. NO. 2 T G A G A C T G A A G C C C G G A A A G T T T T T
SEQ. ID. NO. 3 A T C T G G A G G A G G C G G C C G T T C T G G T

SEQ. ID. NO.1 T G C A T G C C A G C A G C C G G C A C C A G C G
SEQ. ID. NO. 2 T G T G A G G T G T A C A A G G A G C G T C T C T
SEQ. ID. NO. 3 G T G C G C C T G G A G G A C T T C A A C T A C A

SEQ. ID. NO.1 G A T C C A G G A C T T C A A C T A C A C G G A C
SEQ. ID. NO. 2 T T G G G A A G A A G T A C G T C T G G T T C C T
SEQ. ID. NO. 3 A C A A C C A G A C C A T T A C C G A C C A A A T

SEQ. ID. NO.1 C A C A C G C T G G G C A G G A T C A T C C T C A
SEQ. ID. NO. 2 C A T T G G G T G G T A T G C T G A C A A T T G G
SEQ. ID. NO. 3 C T A C C G G G C A A T G A A C T C T T C G T C C

SEQ. ID. NO.1 A T G C C A T G A A C G A G A C C A A C T T C T T
SEQ. ID. NO. 2 T T C A A G A T C T A C G A C C C T T C T A T C A
SEQ. ID. NO. 3 T T T G A G G G T G T C T C T G G C C A T G T G G

FIGURE 1E

SEQ. ID. NO.1 C G G G G T C A C G G G T C A A G T T G T A T T C
SEQ. ID. NO. 2 A C T G C A C A G T G G A T G A G A T G A C T G A
SEQ. ID. NO. 3 T G T T T G A T G C C A G C G G C T C T C G G A T

SEQ. ID. NO.1 C G G A A T G G G G A G A G A A T G G G G A C C A
SEQ. ID. NO. 2 G G C G G T G G A G G G C C A C A T C A C A A C T
SEQ. ID. NO. 3 G G C A T G G A C G C T T A T C G A G C A G C T T

SEQ. ID. NO.1 T T A A A T T T A C T C A A T T T C A A G A C A G
SEQ. ID. NO. 2 G A G A T T G T C A T G C T G A A T C C T G C C A
SEQ. ID. NO. 3 C A G G G T G G C A G C T A C A A G A A G A T T G

SEQ. ID. NO.1 C A G G G A G G T G A A G G T G G G A G A G T A C
SEQ. ID. NO. 2 A T A C C C G C A G C A T T T C C A A C A T G A C
SEQ. ID. NO. 3 G C T A C T A T G A C A G C A C C A A G G A T G A

SEQ. ID. NO.1 A A C G C T G T G G C C G A C A C A C T G G A G A
SEQ. ID. NO. 2 A T C C C A G G A A T T T G T G G A G A A A C T A
SEQ. ID. NO. 3 T C T T T C C T G G T C C A A A A C A G A T A A A

SEQ. ID. NO.1 T C A T C A A T G A C A C C A T C A G G T T C C A
SEQ. ID. NO. 2 A C C A A G C G A C T G A A A A G A C A C C C T G
SEQ. ID. NO. 3 T G G A T T G G A G G G T C C C C C C C A G C T G

SEQ. ID. NO.1 A G G A T C C G A A C C A C C A A A A G A C A A G
SEQ. ID. NO. 2 A G G A G A C A G G A G G C T T C C A G G A G G C
SEQ. ID. NO. 3 A C C A G A C C C T G G T C A T C A A G A C A T T

SEQ. ID. NO.1 A C C A T C A T C C T G G A G C A G C T G C G G A
SEQ. ID. NO. 2 A C C G C T G G C C T A T G A T G C C A T C T G G
SEQ. ID. NO. 3 C C G C T T C C T G T C A C A G A A A C T C T T T

SEQ. ID. NO.1 A G A T C T C C C T A C C T C T C T A C A G C A T
SEQ. ID. NO. 2 G C C T T G G C A C T G G C C C T G A A C A A G A
SEQ. ID. NO. 3 A T C T C C G T C T C A G T T C T C T C A G C C

SEQ. ID. NO.1 C C T C T C T G C C C T C A C C A T C C T C G G G
SEQ. ID. NO. 2 C A T C T G G A G G A G G C G G C C G T T C T G G
SEQ. ID. NO. 3 T G G G C A T T G T C C T A G C T G T T G T C T G

FIGURE 1F

SEQ. ID. NO.1 A T G A T C A T G G C C A G T G C T T T T C T C T
SEQ. ID. NO. 2 T G T G C G C C T G G A G G A C T T C A A C T A C
SEQ. ID. NO. 3 T C T G T C C T T T A A C A T C T A C A A C T C A

SEQ. ID. NO.1 T C T T C A A C A T C A A G A A C C G G A A T C A
SEQ. ID. NO. 2 A A C A A C C A G A C C A T T A C C G A C C A A A
SEQ. ID. NO. 3 C A T G T C C G T T A T A T C C A G A A C T C A C

SEQ. ID. NO.1 G A A G C T C A T A A A G A T G T C G A G T C C A
SEQ. ID. NO. 2 T C T A C C G G G C A A T G A A C T C T T C G T C
SEQ. ID. NO. 3 A G C C C A A C C T G A A C A A C C T G A C T G C

SEQ. ID. NO.1 T A C A T G A A C A A C C T T A T C A T C C T T G
SEQ. ID. NO. 2 C T T T G A G G G T G T C T C T G G C C A T G T G
SEQ. ID. NO. 3 T G T G G G C T G C T C A C T G G C T T T A G C T

SEQ. ID. NO.1 G A G G G A T G C T C T C C T A T G C T T C C A T
SEQ. ID. NO. 2 G T G T T T G A T G C C A G C G G C T C T C G G A
SEQ. ID. NO. 3 G C T G T C T T C C C C C T G G G G C T C G A T G

SEQ. ID. NO.1 A T T T C T C T T T G G C C T T G A T G G A T C C
SEQ. ID. NO. 2 T G G C A T G G A C G C T T A T C G A G C A G C T
SEQ. ID. NO. 3 G T T A C C A C A T T G G G A G G A A C C A G T T

SEQ. ID. NO.1 T T T G T C T C T G A A A A G A C C T T T G A A A
SEQ. ID. NO. 2 T C A G G G T G G C A G C T A C A A G A A G A T T
SEQ. ID. NO. 3 T C C T T T C G T C T G C C A G G C C C G C C T C

SEQ. ID. NO.1 C A C T T T G C A C C G T C A G G A C C T G G A T
SEQ. ID. NO. 2 G G C T A C T A T G A C A G C A C C A A G G A T G
SEQ. ID. NO. 3 T G G C T C C T G G G C C T G G G C T T T A G T C

SEQ. ID. NO.1 T C T C A C C G T G G G C T A C A C G A C C G C T
SEQ. ID. NO. 2 A T C T T T C C T G G T C C A A A A C A G A T A A
SEQ. ID. NO. 3 T G G G C T A C G G T T C C A T G T T C A C C A A

SEQ. ID. NO.1 T T T G G G G C C A T G T T T G C A A A G A C C T
SEQ. ID. NO. 2 A T G G A T T G G A G G G T C C C C C C C A G C T
SEQ. ID. NO. 3 G A T T T G G T G G G T C C A C A C G G T C T T C

FIGURE 1G

SEQ. ID. NO.1 G G A G A G T C C A C G C C A T C T T C A A A A A
SEQ. ID. NO. 2 G A C C A G A C C C T G G T C A T C A A G A C A T
SEQ. ID. NO. 3 A C A A A G A A G G A A G A A A A G A A G G A G T

SEQ. ID. NO.1 T G T G A A A A T G A A G A A G A A G A T C A T C
SEQ. ID. NO. 2 T C C G C T T C C T G T C A C A G A A A C T C T T
SEQ. ID. NO. 3 G G A G G A A G A C T C T G G A A C C C T G G A A

SEQ. ID. NO.1 A A G G A C C A G A A A C T G C T T G T G A T C G
SEQ. ID. NO. 2 T A T C T C C G T C T C A G T T C T C T C C A G C
SEQ. ID. NO. 3 G C T G T A T G C C A C A G T G G G C C T G C T G

SEQ. ID. NO.1 T G G G G G G C A T G C T G C T G A T C G A C C T
SEQ. ID. NO. 2 C T G G G C A T T G T C C T A G C T G T T G T C T
SEQ. ID. NO. 3 G T G G G C A T G G A T G T C C T C A C T C T C G

SEQ. ID. NO.1 G T G T A T C C T G A T C T G C T G G C A G G C T
SEQ. ID. NO. 2 G T C T G T C C T T T A A C A T C T A C A A C T C
SEQ. ID. NO. 3 C C A T C T G G C A G A T C G T G G A C C C T C T

SEQ. ID. NO.1 G T G G A C C C C C T G C G A A G G A C A G T G G
SEQ. ID. NO. 2 A C A T G T C C G T T A T A T C C A G A A C T C A
SEQ. ID. NO. 3 G C A C C G G A C C A T T G A G A C A T T T G C C

SEQ. ID. NO.1 A G A A G T A C A G C A T G G A G C C G G A C C C
SEQ. ID. NO. 2 C A G C C C A A C C T G A A C A A C C T G A C T G
SEQ. ID. NO. 3 A A G G A G G A A C C T A A G G A A G A T A T T G

SEQ. ID. NO.1 A G C A G G A C G G G A T A T C T C C A T C C G C
SEQ. ID. NO. 2 C T G T G G G C T G C T C A C T G G C T T T A G C
SEQ. ID. NO. 3 A C G T C T C T A T T C T G C C C C A G C T G G A

SEQ. ID. NO.1 C C T C T C C T G G A G C A C T G T G A G A A C A
SEQ. ID. NO. 2 T G C T G T C T T C C C C C T G G G G C T C G A T
SEQ. ID. NO. 3 G C A T T G C A G C T C C A G G A A G A T G A A T

SEQ. ID. NO.1 C C C A T A T G A C C A T C T G G C T T G G C A T
SEQ. ID. NO. 2 G G T T A C C A C A T T G G G A G G A A C C A G T
SEQ. ID. NO. 3 A C A T G G C T T G G C A T T T T C T A T G G T T

FIGURE 1H

SEQ. ID. NO.1 C G T C T A T G C C T A C A A G G G A C T T C T C
SEQ. ID. NO. 2 T T C C T T T C G T C T G C C A G G C C C G C C T
SEQ. ID. NO. 3 A C A A G G G G C T G C T G C T G C T G C T G G G

SEQ. ID. NO.1 A T G T T G T T C G G T T G T T T C T T A G C T T
SEQ. ID. NO. 2 C T G G C T C C T G G G C C T G G G C T T T A G T
SEQ. ID. NO. 3 A A T C T T C C T T G C T T A T G A G A C C A A G

SEQ. ID. NO.1 G G G A G A C C C G C A A C G T C A G C A T C C C
SEQ. ID. NO. 2 C T G G G C T A C G G T T C C A T G T T C A C C A
SEQ. ID. NO. 3 A G T G T G T C C A C T G A G A A G A T C A A T G

SEQ. ID. NO.1 C G C A C T C A A C G A C A G C A A G T A C A T C
SEQ. ID. NO. 2 A G A T T T G G T G G G T C C A C A C G G T C T T
SEQ. ID. NO. 3 A T C A C C G G G C T G T G G G C A T G G C T A T

SEQ. ID. NO.1 G G G A T G A G T G T C T A C A A C G T G G G G A
SEQ. ID. NO. 2 C A C A A A G A A G G A A G A A A A G A A G G A G
SEQ. ID. NO. 3 C T A C A A T G T G G C A G T C C T G T G C C T C

SEQ. ID. NO.1 T C A T G T G C A T C A T C G G G G C C G C T G T
SEQ. ID. NO. 2 T G G A G G A A G A C T C T G G A A C C C T G G A
SEQ. ID. NO. 3 A T C A C T G C T C C T G T C A C C A T G A T T C

SEQ. ID. NO.1 C T C C T T C C T G A C C C G G G A C C A G C C C
SEQ. ID. NO. 2 A G C T G T A T G C C A C A G T G G G C C T G C T
SEQ. ID. NO. 3 T G T C C A G C C A G C A G G A T G C A G C C T T

SEQ. ID. NO.1 A A T G T G C A G T T C T G C A T C G T G G C T C
SEQ. ID. NO. 2 G G T G G G C A T G G A T G T C C T C A C T C T C
SEQ. ID. NO. 3 T G C C T T T G C C T C T C T T G C C A T A G T T

SEQ. ID. NO.1 T G G T C A T C A T C T T C T G C A G C A C C A T
SEQ. ID. NO. 2 G C C A T C T G G C A G A T C G T G G A C C C T C
SEQ. ID. NO. 3 T T C T C C T C C T A T A T C A C T C T T G T T G

SEQ. ID. NO.1 C A C C C T C T G C C T G G T A T T C G T G C C G
SEQ. ID. NO. 2 T G C A C C G G A C C A T T G A G A C A T T T G C
SEQ. ID. NO. 3 T G C T C T T T G T G C C C A A G A T G C G C A G

FIGURE 11

SEQ. ID. NO.1 A A G C T C A T C A C C C T G A G A A C A A A C C
SEQ. ID. NO. 2 C A A G G A G G A A C C T A A G G A A G A T A T T
SEQ. ID. NO. 3 G C T G A T C A C C C G A G G G G A A T G G C A G

SEQ. ID. NO.1 C A G A T G C A G C A A C G C A G A A C A G G C G
SEQ. ID. NO. 2 G A C G T C T C T A T T C T G C C C C A G C T G G
SEQ. ID. NO. 3 T C G G A G G C G C A G G A C A C C A T G A A G A

SEQ. ID. NO.1 A T T C C A G T T C A C T C A G A A T C A G A A G
SEQ. ID. NO. 2 A G C A T T G C A G C T C C A G G A A G A T G A A
SEQ. ID. NO. 3 C A G G G T C A T C G A C C A A C A A C A A C G A

SEQ. ID. NO.1 A A A G A A G A T T C T A A A A C G T C C A C C T
SEQ. ID. NO. 2 T A C A T G G C T T G G C A T T T T C T A T G G T
SEQ. ID. NO. 3 G G A G G A G A A G T C C C G G C T G T T G G A G

SEQ. ID. NO.1 C G G T C A C C A G T G T G A A C C A A G C C A G
SEQ. ID. NO. 2 T A C A A G G G G C T G C T G C T G C T G C T G G
SEQ. ID. NO. 3 A A G G A G A A C C G T G A A C T G G A A A A G A

SEQ. ID. NO.1 C A C A T C C C G C C T G G A G G G C C T A C A G
SEQ. ID. NO. 2 G A A T C T T C C T T G C T T A T G A G A C C A A
SEQ. ID. NO. 3 T C A T T G C T G A G A A A G A G G A G C G T G T

SEQ. ID. NO.1 T C A G A A A A C C A T C G C C T G C G A A T G A
SEQ. ID. NO. 2 G A G T G T G T C C A C T G A G A A G A T C A A T
SEQ. ID. NO. 3 C T C T G A A C T G C G C C A T C A A C T C C A G

SEQ. ID. NO.1 A G A T C A C A G A G C T G G A T A A A G A C T T
SEQ. ID. NO. 2 G A T C A C C G G G C T G T G G G C A T G G C T A
SEQ. ID. NO. 3 T C T C G G C A G C A G C T C C G C T C C C G G C

SEQ. ID. NO.1 G G A A G A G G T C A C C A T G C A G C T G C A G
SEQ. ID. NO. 2 T C T A C A A T G T G G C A G T C C T G T G C C T
SEQ. ID. NO. 3 G C C A C C C A C C G A C A C C C C C A G A A C C

SEQ. ID. NO.1 G A C A C A C C A G A A A A G A C C A C C T A C A
SEQ. ID. NO. 2 C A T C A C T G C T C C T G T C A C C A T G A T T
SEQ. ID. NO. 3 C T C T G G G G G C C T G C C C A G G G G A C C C

FIGURE 1J

SEQ. ID. NO.1 T T A A A C A G A A C C A C T A C C A A G A G C T
SEQ. ID. NO. 2 C T G T C C A G C C A G C A G G A T G C A G C C T
SEQ. ID. NO. 3 C C T G A G C C C C C C G A C C G G C T T A G C T

SEQ. ID. NO.1 C A A T G A C A T C C T C A A C C T G G G A A A C
SEQ. ID. NO. 2 T T G C C T T T G C C T C T C T T G C C A T A G T
SEQ. ID. NO. 3 G T G A T G G G A G T C G A G T G C A T T T G C T

SEQ. ID. NO.1 T T C A C T G A G A G C A C A G A T G G A G G A A
SEQ. ID. NO. 2 T T T C T C C T C C T A T A T C A C T C T T G T T
SEQ. ID. NO. 3 T T A T A A G T G A G G G T A G G G T G A G G G A

SEQ. ID. NO.1 A G G C C A T T T T T A A A A A A T C A C C T C G A
SEQ. ID. NO. 2 G T G C T C T T T G T G C C C A A G A T G C G C A
SEQ. ID. NO. 3 G G A C A G G C C A G T A G G G G G A G G G A A A

SEQ. ID. NO.1 T C A A A A T C C C C A G C T A C A G T G G A A C
SEQ. ID. NO. 2 G G C T G A T C A C C C G A G G G G A A T G G C A
SEQ. ID. NO. 3 G G G A G A G G G G A A G G G C A G G G G A C T C

SEQ. ID. NO.1 A C A A C A G A G C C C T C T C G A A C A T G C A
SEQ. ID. NO. 2 G T C G G A G G C G C A G G A C A C C A T G A A G
SEQ. ID. NO. 3 A G G A A G C A G G G G G T C C C C A T C C C C A

SEQ. ID. NO.1 A A G A T C C T A T A G A A G A T A T A A A C T C
SEQ. ID. NO. 2 A C A G G G T C A T C G A C C A A C A A C A A C G
SEQ. ID. NO. 3 G C T G G G A A G A A C A T G C T A T C C A A T C

SEQ. ID. NO.1 T C C A G A A C A C A T C C A G C G T C G G C T G
SEQ. ID. NO. 2 A G G A G G A G A A G T C C C G G C T G T T G G A
SEQ. ID. NO. 3 T C A T C T C T T G T A A A T A C A T G T C C C C

SEQ. ID. NO.1 T C C C T C C A G C T C C C C A T C C T C C A C C
SEQ. ID. NO. 2 G A A G G A G A A C C G T G A A C T G G A A A A G
SEQ. ID. NO. 3 C T G T G A G T T C T G G G C T G A T T T G G G T

SEQ. ID. NO.1 A C G C C T A C C T C C C A T C C A T C G G A G G
SEQ. ID. NO. 2 A T C A T T G C T G A G A A A G A G G A G C G T G
SEQ. ID. NO. 3 C T C T C A T A C C T C T G G G A A A C A G A C C

FIGURE 1K

SEQ. ID. NO.1 C G T G G A C G C C A G C T G T G T C A G C C C C
SEQ. ID. NO. 2 T C T C T G A A C T G C G C C A T C A G C T C C A
SEQ. ID. NO. 3 T T T T T C T C T C T T A C T G C T T C A T G T A

SEQ. ID. NO.1 T G C G T C A G C C C C A C C G C C A G C C C C C
SEQ. ID. NO. 2 G T C T C G G C A G C A G C T C C G C T C C C G G
SEQ. ID. NO. 3 A T T T T G T A T C A C C T C T T C A C A A T T T

SEQ. ID. NO.1 G C C A C A G A C A T G T G C C A C C C T C C T T
SEQ. ID. NO. 2 C G C C A C C C A C C G A C A C C C C C A G A A C
SEQ. ID. NO. 3 A G T T C G T A C C T G G C T T G A A G C T G C T

SEQ. ID. NO.1 C C G A G T C A T G G T C T C G G G C C T G
SEQ. ID. NO. 2 C C T C T G G G G G C C T G C C C A G G G G A C C
SEQ. ID. NO. 3 C A C T G C T C A C A C G C T G C C T C C T C A G

SEQ. ID. NO.1
SEQ. ID. NO. 2 C C C T G A G C C C C C C G A C C G G C T T A G C
SEQ. ID. NO. 3 C A G C C T C A C T G C A T C T T T C T C T T C C

SEQ. ID. NO.1
SEQ. ID. NO. 2 T G T G A T G G G A G T C G A G T G C A T T T G C
SEQ. ID. NO. 3 C A T G C A A C A C C C T C T T C T A G T T A C C

SEQ. ID. NO.1
SEQ. ID. NO. 2 T T T A T A A G T G A G G G T A G G G T G A G G G
SEQ. ID. NO. 3 A C G G C A A C C C C T

SEQ. ID. NO.1
SEQ. ID. NO. 2 A G G A C A G G C C A G T A G G G G G A G G G A A
SEQ. ID. NO. 3

SEQ. ID. NO.1
SEQ. ID. NO. 2 A G G G A G A G G G G A A G G G C A G G G G A C T
SEQ. ID. NO. 3

SEQ. ID. NO.1
SEQ. ID. NO. 2 C A G G A A G C A G G G G G T C C C C A T C C C C
SEQ. ID. NO. 3

FIGURE 1L

SEQ. ID. NO.1
SEQ. ID. NO.2 A G C T G G G A A G A A C A T G C T A T C C A A T
SEQ. ID. NO.3

SEQ. ID. NO.1
SEQ. ID. NO.2 C T C A T C T C T T G T A A A T A C A T G T C C C
SEQ. ID. NO.3

SEQ. ID. NO.1
SEQ. ID. NO.2 C C T G T G A G T T C T G G G C T G A T T T G G G
SEQ. ID. NO.3

SEQ. ID. NO.1
SEQ. ID. NO.2 T C T C T C A T A C C T C T G G G A A A C A G A C
SEQ. ID. NO.3

SEQ. ID. NO.1
SEQ. ID. NO.2 C T T T T T C T C T C T T A C T G C T T C A T G T
SEQ. ID. NO.3

SEQ. ID. NO.1
SEQ. ID. NO.2 A A T T T T G T A T C A C C T C T T C A C A A T T
SEQ. ID. NO.3

SEQ. ID. NO.1
SEQ. ID. NO.2 T A G T T C G T A C C T G G C T T G A A G C T G C
SEQ. ID. NO.3

SEQ. ID. NO.1
SEQ. ID. NO.2 T C A C T G C T C A C A C G C T G C C T C C T C A
SEQ. ID. NO.3

SEQ. ID. NO.1
SEQ. ID. NO.2 G C A G C C T C A C T G C A T C T T T C T C T T C
SEQ. ID. NO.3

SEQ. ID. NO.1
SEQ. ID. NO.2 C C A T G C A A C A C C C T C T T C T A G T T A C
SEQ. ID. NO.3

FIGURE 1M

SEQ. ID. NO.1
SEQ. ID. NO.2 C A C G G C A A C C C C T G C A G C T C C T C T G
SEQ. ID. NO.3

SEQ. ID. NO.1
SEQ. ID. NO.2 C C T T T G T G C T C T G T T C C T G T C C A G C
SEQ. ID. NO.3

SEQ. ID. NO.1
SEQ. ID. NO.2 A G G G G T C T C C C A A C A A G T G C T C T T T
SEQ. ID. NO.3

SEQ. ID. NO.1
SEQ. ID. NO.2 C C A C C C C A A A G G G G C C T C T C C T T T T
SEQ. ID. NO.3

SEQ. ID. NO.1
SEQ. ID. NO.2 C T C C A C T G T C A T A A T C T C T T T C C A T
SEQ. ID. NO.3

SEQ. ID. NO.1
SEQ. ID. NO.2 C T T A C T T G C C C T T C T A T A C T T T C T C
SEQ. ID. NO.3

SEQ. ID. NO.1
SEQ. ID. NO.2 A C A T G T G G C T C C C C C T G A A T T T T G C
SEQ. ID. NO.3

SEQ. ID. NO.1
SEQ. ID. NO.2 T T C C T T T G G G G A G C T C A T T C T T T C G
SEQ. ID. NO.3

SEQ. ID. NO.1
SEQ. ID. NO.2 C C A A G G T C A C A T G C T C C C T T G C C T C
SEQ. ID. NO.3

SEQ. ID. NO.1
SEQ. ID. NO.2 T G G C T C C G T G C A
SEQ. ID. NO.3

FIGURE 1N

ClustalW Formatted Alignments

SEQ. ID. NO. 4 M A S P R S S S G Q P G P X P P P P P P P A R L L L
 SEQ. ID. NO. 5 M L L L L L V P L F L R P L G A G G A Q T P N A T
 SEQ. ID. NO. 6 M G P G G P C T P V G W P L P L L L V M A A G V A
 SEQ. ID. NO. 7 M L L L L L L A P L F L R P P G A G G A Q T P N A
 SEQ. ID. NO. 8 M G P G A P F A R V G W P L P L L V V M A A G V A

SEQ. ID. NO. 4 L L L L P L L L P L A P G A W G W A R G A P R P P
 SEQ. ID. NO. 5 S E G C Q I I H P P W E G G I R Y R G L T R D Q V
 SEQ. ID. NO. 6 P V W A S H S P H L P R P H P R V P P H P S S E R
 SEQ. ID. NO. 7 T S E G C Q I I H P P W E G G I R Y R G L T R D Q
 SEQ. ID. NO. 8 P V W A S H S P H L P R P H S R V P P H P S S E R

SEQ. ID. NO. 4 P S S P - P L S I M G L M P L T K E V A K G S I G
 SEQ. ID. NO. 5 K A I N F L P V D Y E I E Y V C R G E R E V V G P
 SEQ. ID. NO. 6 R A V Y I G A L F P M S G G W P G G Q A C Q P A V
 SEQ. ID. NO. 7 V K A I N F L P V D Y E I E Y V C R G E R E V V G
 SEQ. ID. NO. 8 R A V Y I G A L F P M S G G W P G G Q A C Q P A V

SEQ. ID. NO. 4 R G V L P A V E L A I E Q I R N E - S L L R P Y F
 SEQ. ID. NO. 5 K V R K C L A N G S W T D M D T P S R C V R I C S
 SEQ. ID. NO. 6 E M A L E D V N S R R D I L P D Y E L K L I H H D
 SEQ. ID. NO. 7 P K V R K C L A N G S W T D M D T P S R C V R I C
 SEQ. ID. NO. 8 E M A L E D V N S R R D I L P D Y E L K L I H H D

SEQ. ID. NO. 4 L D L R L Y D T E C D N A K G L K A F Y D A I K Y
 SEQ. ID. NO. 5 K S Y L T L E N G K V F L T G G D L P A L D G A R
 SEQ. ID. NO. 6 S K C D P G Q A T K Y L Y E L L Y N D P I K I I L
 SEQ. ID. NO. 7 S K S Y L T L E N G K V F L T G G D L P A L D G A
 SEQ. ID. NO. 8 S K C D P G Q A T K Y L Y E L L Y N D P I K I I L

SEQ. ID. NO. 4 G P N H L M V F G G V C P S V T S I I A E S L Q G
 SEQ. ID. NO. 5 V E F R C D P D F H L V G S S R S V C S Q G Q W S
 SEQ. ID. NO. 6 M P G C S S V S T L V A E A A R M W N L I V L S Y
 SEQ. ID. NO. 7 R V D F R C D P D F H L V G S S R S I C S Q G Q W
 SEQ. ID. NO. 8 M P G C S S V S T L V A E A A R M W N L I V L S Y

SEQ. ID. NO. 4 W N L V Q L S F A A T T P V L A D K K K Y P Y F F
 SEQ. ID. NO. 5 T P K P H C Q V N R T P H S E R R A V Y I G A L F
 SEQ. ID. NO. 6 G S S S P A L S N R Q R F P T F F R T H P S A T L
 SEQ. ID. NO. 7 S T P K P H C Q V N R T P H S E R R A V Y I G A L
 SEQ. ID. NO. 8 G S S S P A L S N R Q R F P T F F R T H P S A T L

FIGURE 2A

SEQ. ID. NO. 4 R T V P S D N A V N P A I L K L L K H Y Q W K R V
 SEQ. ID. NO. 5 P M S G G W P G G Q A C Q P A V E M A L E D V N S
 SEQ. ID. NO. 6 H N P T R V K L F E K W G W K K I A T I Q Q T T E
 SEQ. ID. NO. 7 F P M S G G W P G G Q A C Q P A V E M A L E D V N
 SEQ. ID. NO. 8 H N P T R V K L F E K W G W K K I A T I Q Q T T E

SEQ. ID. NO. 4 G T L T Q D V Q R F S E V R N D L T G V L Y G E D
 SEQ. ID. NO. 5 R R D I L P D Y E L K L I H H D S K C D P G Q A T
 SEQ. ID. NO. 6 V F T S T L D D L E E R V K E A G I E I T F R Q S
 SEQ. ID. NO. 7 S R R D I L P D Y E L K L I H H D S K C D P G Q A
 SEQ. ID. NO. 8 V F T S T L D D L E E R V K E A G I E I T F R Q S

SEQ. ID. NO. 4 I E I S D T E S F S N D P C T S V K K L K G N D V
 SEQ. ID. NO. 5 K Y L Y E L L Y N D P I K I I L M P G C S S V S T
 SEQ. ID. NO. 6 F F S D P A V P V K N L K R Q D A R I I V G L F Y
 SEQ. ID. NO. 7 T K Y L Y E L L Y N D P I K I I L M P G C S S V S
 SEQ. ID. NO. 8 F F S D P A V P V K N L K R Q D A R I I V G L F Y

SEQ. ID. NO. 4 R I I L G Q F D Q N M A A K V F C C A Y E E N M Y
 SEQ. ID. NO. 5 L V A E A A R M W N L I V L S Y G S S S P A L S N
 SEQ. ID. NO. 6 E T E A R K V F C E V Y K E R L F G K K Y V W F L
 SEQ. ID. NO. 7 T L V A E A A R M W N L I V L S Y G S S S P A L S
 SEQ. ID. NO. 8 E T E A R K V F C E V Y K E R L F G K K Y V W F L

SEQ. ID. NO. 4 G S K Y Q W I I P G W Y E P S W W E Q V H T E A N
 SEQ. ID. NO. 5 R Q R F P T F F R T H P S A T L H N P T R V K L F
 SEQ. ID. NO. 6 I G W Y A D N W F K T Y D P S I N C T V E E M T E
 SEQ. ID. NO. 7 N R Q R F P T F F R T H P S A T L H N P T R V K L
 SEQ. ID. NO. 8 I G W Y A D N W F K I Y D P S I N C T V D E M T E

SEQ. ID. NO. 4 S S R C L R K N L L A A M E G Y I G V D F E P L S
 SEQ. ID. NO. 5 E K W G W K K I A T I Q Q T T E V F T S T L D D L
 SEQ. ID. NO. 6 A V E G H I T T E I V M L N P A N T R S I S N M T
 SEQ. ID. NO. 7 F E K W G W K K I A T I Q Q T T E V F T S T L D D
 SEQ. ID. NO. 8 A V E G H I T T E I V M L N P A N T R S I S N M T

SEQ. ID. NO. 4 S K Q I K T I S G K T P Q Q Y E R E Y N N K R S G
 SEQ. ID. NO. 5 E E R V K E A G I E I T F R Q S F F S D P A V P V
 SEQ. ID. NO. 6 S Q E F V E K L T K R L K R H P E E T G G F Q E A
 SEQ. ID. NO. 7 L E E R V K E A G I E I T F R Q S F F S D P A V P
 SEQ. ID. NO. 8 S Q E F V E K L T K R L K R H P E E T G G F Q E A

FIGURE 2B

SEQ. ID. NO. 4 V G P S K F H G Y A Y D G I W V I A K T L Q R A M
 SEQ. ID. NO. 5 K N L K R Q D A R I I V G L F Y E T E A R K V F C
 SEQ. ID. NO. 6 P L A Y D A I W A L A L A L N K T S G G G G R S G
 SEQ. ID. NO. 7 V K N L K R Q D A R I I V G L F Y E T E A R K V F
 SEQ. ID. NO. 8 P L A Y D A I W A L A L A L N K T S G G G G R S G

SEQ. ID. NO. 4 E T L H A S S R H Q R I Q D F N Y T D H T L G R I
 SEQ. ID. NO. 5 E V Y K E R L F G K K Y V W F L I G W Y A D N W F
 SEQ. ID. NO. 6 V R L E D F N Y N N Q T I T D Q I Y R A M N S S S
 SEQ. ID. NO. 7 C E V Y K E R L F G K K Y V W F L I G W Y A D N W
 SEQ. ID. NO. 8 V R L E D F N Y N N Q T I T D Q I Y R A M N S S S

SEQ. ID. NO. 4 I L N A M N E T N F F G V T G Q V V F R N G E R M
 SEQ. ID. NO. 5 K T Y D P S I N C T V E E M T E A V E G H I T T E
 SEQ. ID. NO. 6 F E G V S G H V V F D A S G S R M A W T L I E Q L
 SEQ. ID. NO. 7 F K I Y D P S I N C T V D E M T E A V E G H I T T
 SEQ. ID. NO. 8 F E G V S G H V V F D A S G S R M A W T L I E Q L

SEQ. ID. NO. 4 G T I K F T Q F Q D S R E V K V G E Y N A V A D T
 SEQ. ID. NO. 5 I V M L N P A N T R S I S N M T S Q E F V E K L T
 SEQ. ID. NO. 6 Q G G S Y K K I G Y Y D S T K D D L S W S K T D K
 SEQ. ID. NO. 7 E I V M L N P A N T R S I S N M T S Q E F V E K L
 SEQ. ID. NO. 8 Q G G S Y K K I G Y Y D S T K D D L S W S K T D K

SEQ. ID. NO. 4 L E I I N D T I R F Q G S E P P K D K T I I L E Q
 SEQ. ID. NO. 5 K R L K R H P E E T G G F Q E A P L A Y D A I W A
 SEQ. ID. NO. 6 W I G G S P P A D Q I L V I K T F R F L S Q K L F
 SEQ. ID. NO. 7 T K R L K R H P E E T G G F Q E A P L A Y D A I W
 SEQ. ID. NO. 8 W I G G S P P A D Q T L V I K T F R F L S Q K L F

SEQ. ID. NO. 4 L R K I S L P L Y S I L S A L T I L G M I M A S A
 SEQ. ID. NO. 5 L A L A L N K T S G G G G R S G V R L E D F N Y N
 SEQ. ID. NO. 6 I S V S V L S S L G I V L A V V C L S F N I Y N S
 SEQ. ID. NO. 7 A L A L A L N K T S G G G G R S G V R L E D F N Y
 SEQ. ID. NO. 8 I S V S V L S S L G I V L A V V C L S F N I Y N S

SEQ. ID. NO. 4 F L F F N I K N R N Q K L I K M S S P Y M N N L I
 SEQ. ID. NO. 5 N Q T I T D Q I Y R A M N S S S F E G V S G H V V
 SEQ. ID. NO. 6 H V R Y I Q N S Q P N L N N L T A V G C S L A L A
 SEQ. ID. NO. 7 N N Q T I T D Q I Y R A M N S S S F E G V S G H V
 SEQ. ID. NO. 8 H V R Y I Q N S Q P N L N N L T A V G C S L A L A

FIGURE 2C

SEQ. ID. NO. 4 I L G G M L S Y A S I F L F G L D G S F V S E K T
 SEQ. ID. NO. 5 F D A S G S R M A W T L I E Q L Q G G S Y K K I G
 SEQ. ID. NO. 6 A V F P L G L D G Y H I G R S Q F P F V C Q A R L
 SEQ. ID. NO. 7 V F D A S G S R M A W T L I E Q L Q G G S Y K K I
 SEQ. ID. NO. 8 A V F P L G L D G Y H I G R N Q F P F V C Q A R L

SEQ. ID. NO. 4 F E T L C T V R T W I L T V G Y T T A F G A M F A
 SEQ. ID. NO. 5 Y Y D S T K D D L S W S K T D K W I G G S P P A D
 SEQ. ID. NO. 6 W L L G L G F S L G Y G S M F T K I W W V H T V F
 SEQ. ID. NO. 7 G Y Y D S T K D D L S W S K T D K W I G G S P P A
 SEQ. ID. NO. 8 W L L G L G F S L G Y G S M F T K I W W V H T V F

SEQ. ID. NO. 4 K T W R V H A I F K N V K M K K K I I K D Q K L L
 SEQ. ID. NO. 5 Q I L V I K T F R F L S Q K L F I S V S V L S S L
 SEQ. ID. NO. 6 T K K E E K K E W R K T L E P W K L Y A T V G L L
 SEQ. ID. NO. 7 D Q T L V I K T F R F L S Q K L F I S V S V L S S
 SEQ. ID. NO. 8 T K K E E K K E W R K T L E P W K L Y A T V G L L

SEQ. ID. NO. 4 V I V G G M L L I D L C I L I C W Q A V D P L R R
 SEQ. ID. NO. 5 G I V L A V V C L S F N I Y N S H V R Y I Q N S Q
 SEQ. ID. NO. 6 V G M D V L T L A I W Q I V D P L H R T I E T F A
 SEQ. ID. NO. 7 L G I V L A V V C L S F N I Y N S H V R Y I Q N S
 SEQ. ID. NO. 8 V G M D V L T L A I W Q I V D P L H R T I E T F A

SEQ. ID. NO. 4 T V E K Y S M E P D P A G R D I S I R P L L E H C
 SEQ. ID. NO. 5 P N L N N L T A V G C S L A L A A V F P L G L D G
 SEQ. ID. NO. 6 K E E P K E D I D V S I L P Q L E H C S S K K M N
 SEQ. ID. NO. 7 Q P N L N N L T A V G C S L A L A A V F P L G L D
 SEQ. ID. NO. 8 K E E P K E D I D V S I L P Q L E H C S S R K M N

SEQ. ID. NO. 4 E N T H M T I W L G I V Y A Y K G L L M L F G C F
 SEQ. ID. NO. 5 Y H I G R S Q F P F V C Q A R L W L L G L G F S L
 SEQ. ID. NO. 6 T W L G I F Y G Y K G L L L L L G I F L A Y E T K
 SEQ. ID. NO. 7 G Y H I G R N Q F P F V C Q A R L W L L G L G F S
 SEQ. ID. NO. 8 T W L G I F Y G Y K G L L L L L G I F L A Y E T K

SEQ. ID. NO. 4 L A W E T R N V S I P A L N D S K Y I G M S V Y N
 SEQ. ID. NO. 5 G Y G S M F T K I W W V H T V F T K K E E K K E W
 SEQ. ID. NO. 6 S V S T E K I N D H R A V G M A I Y N V A V L C L
 SEQ. ID. NO. 7 L G Y G S M F T K I W W V H T V F T K K E E K K E
 SEQ. ID. NO. 8 S V S T E K I N D H R A V G M A I Y N V A V L C L

FIGURE 2D

SEQ. ID. NO. 4 V G I M C I I G A A V S F L T R D Q P N V Q F C I
 SEQ. ID. NO. 5 R K T L E P W K L Y A T V G L L V G M D V L T L A
 SEQ. ID. NO. 6 I T A P V T M I L S S Q Q D A A F A F A S L A I V
 SEQ. ID. NO. 7 W R K T L E P W K L Y A T V G L L V G M D V L T L
 SEQ. ID. NO. 8 I T A P V T M I L S S Q Q D A A F A F A S L A I V

SEQ. ID. NO. 4 V A L V I I F C S T I T L C L V F V P K L I T L R
 SEQ. ID. NO. 5 I W Q I V D P L H R T I E T F A K E E P K E D I D
 SEQ. ID. NO. 6 F S S Y I T L V V L F V P K M R R L I T R G E W Q
 SEQ. ID. NO. 7 A I W Q I V D P L H R T I E T F A K E E P K E D I
 SEQ. ID. NO. 8 F S S Y I T L V V L F V P K M R R L I T R G E W Q

SEQ. ID. NO. 4 T N P D A A T Q N R R F Q F T Q N Q K K E D S K T
 SEQ. ID. NO. 5 V S I L P Q L E H C S S K K M N T W L G I F Y G Y
 SEQ. ID. NO. 6 S E T Q D T M K T G S S T N N N E E E K S R L L E
 SEQ. ID. NO. 7 D V S I L P Q L E H C S S R K M N T W L G I F Y G
 SEQ. ID. NO. 8 S E A Q D T M K T G S S T N N N E E E K S R L L E

SEQ. ID. NO. 4 S T S V T S V N Q A S T S R L E G L Q S E N H R L
 SEQ. ID. NO. 5 K G L L L L L G I F L A Y E T K S V S T E K I N D
 SEQ. ID. NO. 6 K E N R E L E K I I A E K E E R V S E L R H Q L Q
 SEQ. ID. NO. 7 Y K G L L L L L G I F L A Y E T K S V S T E K I N
 SEQ. ID. NO. 8 K E N R E L E K I I A E K E E R V S E L R H Q L Q

SEQ. ID. NO. 4 R M K I T E L D K D L E E V T M Q L Q D T P E K T
 SEQ. ID. NO. 5 H R A V G M A I Y N V A V L C L I T A P V T M I L
 SEQ. ID. NO. 6 S R Q Q L R S R R H P P T P P D P S G G L P R G P
 SEQ. ID. NO. 7 D H R A V G M A I Y N V A V L C L I T A P V T M I
 SEQ. ID. NO. 8 S R Q Q L R S R R H P P T P P E P S G G L P R G P

SEQ. ID. NO. 4 T Y I K Q N H Y Q E L N D I L N L G N F T E S T D
 SEQ. ID. NO. 5 S S Q Q D A A F A F A S L A I V F S S Y I T L V V
 SEQ. ID. NO. 6 S E P P D R L S C D G S R V H L L Y K
 SEQ. ID. NO. 7 L S S Q Q D A A F A F A S L A I V F S S Y I T L V
 SEQ. ID. NO. 8 P E P P D R L S C D G S R V H L L Y K

SEQ. ID. NO. 4 G G K A I L K N H L D Q N P Q L Q W N T T E P S R
 SEQ. ID. NO. 5 L F V P K M R R L I T R G E W Q S E T Q D T M K T
 SEQ. ID. NO. 6
 SEQ. ID. NO. 7 V L F V P K M R R L I T R G E W Q S E A Q D T M K
 SEQ. ID. NO. 8

FIGURE 2E

SEQ. ID. NO. 4 T C K D P I E D I N S P E H I Q R R L S L Q L P I
SEQ. ID. NO. 5 G S S T N N N E E E K S R L L E K E N R E L E K I
SEQ. ID. NO. 6
SEQ. ID. NO. 7 T G S S T N N N E E E K S R L L E K E N R E L E K
SEQ. ID. NO. 8

SEQ. ID. NO. 4 L H H A Y L P S I G G V D A S C V S P C V S P T A
SEQ. ID. NO. 5 I A E K E E R V S E L R H Q L Q S R Q Q L R S R R
SEQ. ID. NO. 6
SEQ. ID. NO. 7 I I A E K E E R V S E L R H Q L Q S R Q Q L R S R
SEQ. ID. NO. 8

SEQ. ID. NO. 4 S P R H R H V P P S F R V M V S G L
SEQ. ID. NO. 5 H P P T P P D P S G G L P R G P S E P P D R L S C
SEQ. ID. NO. 6
SEQ. ID. NO. 7 R H P P T P P E P S G G L P R G P P E P P D R L S
SEQ. ID. NO. 8

SEQ. ID. NO. 4
SEQ. ID. NO. 5 D G S R V H L L Y K
SEQ. ID. NO. 6
SEQ. ID. NO. 7 C D G S R V H L L Y K
SEQ. ID. NO. 8

FIGURE 2F

ATG GCA TTT TAT AGC
 Met Ala Phe Tyr Ser>

TGC TGC TGG GTC CTC TTG GCA CTC ACC TGG CAC ACC TCT GCC TAC GGG CCA GAC
 Cys Cys Trp Val Leu Leu Ala Leu Thr Trp His Thr Ser Ala Tyr Gly Pro Asp>

CAG CGA GCC CAA AAG AAG GGG GAC ATT ATC CTT GGG GGG CTC TTT CCT ATT CAT
 Gln Arg Ala Gln Lys Lys Gly Asp Ile Ile Leu Gly Gly Leu Phe Pro Ile His>

TTT GGA GTA GCA GCT AAA GAT CAA GAT CTC AAA TCA AGG CCG GAG TCT GTG GAA
 Phe Gly Val Ala Ala Lys Asp Gln Asp Leu Lys Ser Arg Pro Glu Ser Val Glu>

TGT ATC AGG TAT AAT TTC CGT GGG TTT CGC TGG TTA CAG GCT ATG ATA TTT GCC
 Cys Ile Arg Tyr Asn Phe Arg Gly Phe Arg Trp Leu Gln Ala Met Ile Phe Ala>

ATA GAG GAG ATA AAC AGC AGC CCA GCC CTT CTT CCC AAC TTG ACG CTG GGA TAC
 Ile Glu Glu Ile Asn Ser Ser Pro Ala Leu Leu Pro Asn Leu Thr Leu Gly Tyr>

AGG ATA TTT GAC ACT TGC AAC ACC GTT TCT AAG GCC TTG GAA GCC ACC CTG AGT
 Arg Ile Phe Asp Thr Cys Asn Thr Val Ser Lys Ala Leu Glu Ala Thr Leu Ser>

TTT GTT GCT CAA AAC AAA ATT GAT TCT TTG AAC CTT GAT GAG TTC TGC AAC TGC
 Phe Val Ala Gln Asn Lys Ile Asp Ser Leu Asn Leu Asp Glu Phe Cys Asn Cys>

TCA GAG CAC ATT CCC TCT ACG ATT GCT GTG GTG GGA GCA ACT GGC TCA GGC GTC
 Ser Glu His Ile Pro Ser Thr Ile Ala Val Val Gly Ala Thr Gly Ser Gly Val>

TCC ACG GCA GTG GCA AAT CTG CTG GGG CTC TTC TAC ATT CCC CAG GTC AGT TAT
 Ser Thr Ala Val Ala Asn Leu Leu Gly Leu Phe Tyr Ile Pro Gln Val Ser Tyr>

GCC TCC TCC AGC AGA CTC CTC AGC AAC AAG AAT CAA TTC AAG TCT TTC CTC CGA
 Ala Ser Ser Ser Arg Leu Leu Ser Asn Lys Asn Gln Phe Lys Ser Phe Leu Arg>

ACC ATC CCC AAT GAT GAG CAC CAG GCC ACT GCC ATG GCA GAC ATC ATC GAG TAT
 Thr Ile Pro Asn Asp Glu His Gln Ala Thr Ala Met Ala Asp Ile Ile Glu Tyr>

TTC CGC TGG AAC TGG GTG GGC ACA ATT GCA GCT GAT GAC GAC TAT GGG CGG CCG
 Phe Arg Trp Asn Trp Val Gly Thr Ile Ala Ala Asp Asp Asp Tyr Gly Arg Pro>

GGG ATT GAG AAA TTC CGA GAG GAA GCT GAG GAA AGG GAT ATC TGC ATC GAC TTC
 Gly Ile Glu Lys Phe Arg Glu Glu Ala Glu Glu Arg Asp Ile Cys Ile Asp Phe>

AGT GAA CTC ATC TCC CAG TAC TCT GAT GAG GAA GAG ATC CAG CAT GTG GTA GAG
 Ser Glu Leu Ile Ser Gln Tyr Ser Asp Glu Glu Glu Ile Gln His Val Val Glu>

GTG ATT CAA AAT TCC ACG GCC AAA GTC ATC GTG GTT TTC TCC AGT GGC CCA GAT
 Val Ile Gln Asn Ser Thr Ala Lys Val Ile Val Val Phe Ser Ser Gly Pro Asp>

FIGURE 3A

CTT GAG CCC CTC ATC AAG GAG ATT GTC CGG CGC AAT ATC ACG GGC AAG ATC TGG
 Leu Glu Pro Leu Ile Lys Glu Ile Val Arg Arg Asn Ile Thr Gly Lys Ile Trp>
 CTG GCC AGC GAG GCC TGG GCC AGC TCC TCC CTG ATC GCC ATG CCT CAG TAC TTC
 Leu Ala Ser Glu Ala Trp Ala Ser Ser Ser Leu Ile Ala Met Pro Gln Tyr Phe>
 CAC GTG GTT GGC GGC ACC ATT GGA TTC GCT CTG AAG GCT GGG CAG ATC CCA GGC
 His Val Val Gly Gly Thr Ile Gly Phe Ala Leu Lys Ala Gly Gln Ile Pro Gly>
 TTC CGG GAA TTC CTG AAG AAG GTC CAT CCC AGG AAG TCT GTC CAC AAT GGT TTT
 Phe Arg Glu Phe Leu Lys Lys Val His Pro Arg Lys Ser Val His Asn Gly Phe>
 GCC AAG GAG TTT TGG GAA GAA ACA TTT AAC TGC CAC CTC CAA GAA GGT GCA AAA
 Ala Lys Glu Phe Trp Glu Glu Thr Phe Asn Cys His Leu Gln Glu Gly Ala Lys>
 GGA CCT TTA CCT GTG GAC ACC TTT CTG AGA GGT CAC GAA GAA AGT GGC GAC AGG
 Gly Pro Leu Pro Val Asp Thr Phe Leu Arg Gly His Glu Glu Ser Gly Asp Arg>
 TTT AGC AAC AGC TCG ACA GCC TTC CGA CCC CTC TGT ACA GGG GAT GAG AAC ATC
 Phe Ser Asn Ser Ser Thr Ala Phe Arg Pro Leu Cys Thr Gly Asp Glu Asn Ile>
 AGC AGT GTC GAG ACC CCT TAC ATA GAT TAC ACG CAT TTA CGG ATA TCC TAC AAT
 Ser Ser Val Glu Thr Pro Tyr Ile Asp Tyr Thr His Leu Arg Ile Ser Tyr Asn>
 GTG TAC TTA GCA GTC TAC TCC ATT GCC CAC GCC TTG CAA GAT ATA TAT ACC TGC
 Val Tyr Leu Ala Val Tyr Ser Ile Ala His Ala Leu Gln Asp Ile Tyr Thr Cys>
 TTA CCT GGG AGA GGG CTC TTC ACC AAT GGC TCC TGT GCA GAC ATC AAG AAA GTT
 Leu Pro Gly Arg Gly Leu Phe Thr Asn Gly Ser Cys Ala Asp Ile Lys Lys Val>
 GAG GCG TGG CAG GTC CTG AAG CAC CTA CGG CAT CTA AAC TTT ACA AAC AAT ATG
 Glu Ala Trp Gln Val Leu Lys His Leu Arg His Leu Asn Phe Thr Asn Asn Met>
 GGG GAG CAG GTG ACC TTT GAT GAG TGT GGT GAC CTG GTG GGG AAC TAT TCC ATC
 Gly Glu Gln Val Thr Phe Asp Glu Cys Gly Asp Leu Val Gly Asn Tyr Ser Ile>
 ATC AAC TGG CAC CTC TCC CCA GAG GAT GGC TCC ATC CTG TTT AAG GAA GTC GGG
 Ile Asn Trp His Leu Ser Pro Glu Asp Gly Ser Ile Val Phe Lys Glu Val Gly>
 TAT TAC AAC GTC TAT GCC AAG AAG GGA GAA AGA CTC TTC ATC AAC GAG GAG AAA
 Tyr Tyr Asn Val Tyr Ala Lys Lys Gly Glu Arg Leu Phe Ile Asn Glu Glu Lys>
 ATC CTG TGG AGT GGG TTC TCC AGG GAG CTG CCC TTC TCC AAC TGC AGC CGA GAC
 Ile Leu Trp Ser Gly Phe Ser Arg Glu Val Pro Phe Ser Asn Cys Ser Arg Asp>
 TGC CTG GCA GGG ACC AGG AAA GGG ATC ATT GAG GGG GAG CCC ACC TGC TGC TTT
 Cys Leu Ala Gly Thr Arg Lys Gly Ile Ile Glu Gly Glu Pro Thr Cys Cys Phe>
 GAG TGT GTG GAG TGT CCT GAT GGG GAG TAT AGT GAT GAG ACA GAT GCC AGT GCC
 Glu Cys Val Glu Cys Pro Asp Gly Glu Tyr Ser Asp Glu Thr Asp Ala Ser Ala>

1753

FIGURE 3B


TGT AAC AAG TGC CCA GAT GAC TTC TGG TCC AAT GAG AAC CAC ACC TCC TGC ATT
 Cys Asn Lys Cys Pro Asp Asp Phe Trp Ser Asn Glu Asn His Thr Ser Cys Ile>
 GCC AAG GAG ATC GAG TTT CTG TCG TGG ACG GAG CCC TTT GGG ATC GCA CTC ACC
 Ala Lys Glu Ile Glu Phe Leu Ser Trp Thr Glu Pro Phe Gly Ile Ala Leu Thr>
 CTC TTT GCC GTG CTG GGC ATT TTC CTG ACA GCC TTT GTG CTG GGT GTG TTT ATC
 Leu Phe Ala Val Leu Gly Ile Phe Leu Thr Ala Phe Val Leu Gly Val Phe Ile>
 AAG TTC CGC AAC ACA CCC ATT GTC AAG GCC ACC AAC CGA GAG CTC TCC TAC CTC
 Lys Phe Arg Asn Thr Pro Ile Val Lys Ala Thr Asn Arg Glu Leu Ser Tyr Leu>
 CTC CTC TTC TCC CTG CTC TGC TGC TTC TCC AGC TCC CTG TTC TTC ATC GGG GAG
 Leu Leu Phe Ser Leu Leu Cys Cys Phe Ser Ser Ser Leu Phe Phe Ile Gly Glu>
 CCC CAG GAC TGG ACG TGC CGC CTG CGC CAG CCG GCC TTT GGC ATC AGC TTC GTG
 Pro Gln Asp Trp Thr Cys Arg Leu Arg Gln Pro Ala Phe Gly Ile Ser Phe Val>
 CTC TGC ATC TCA TGC ATC CTG GTG AAA ACC AAC CGT GTC CTC CTG GTG TTT GAG
 Leu Cys Ile Ser Cys Ile Leu Val Lys Thr Asn Arg Val Leu Leu Val Phe Glu>
 GCC AAG ATC CCC ACC AGC TTC CAC CGC AAG TGG TGG GGG CTC AAC CTG CAG TTC
 Ala Lys Ile Pro Thr Ser Phe His Arg Lys Trp Trp Gly Leu Asn Leu Gln Phe>
 CTG CTG GTT TTC CTC TGC ACC TTC ATG CAG ATT GTC ATC TGT GTG ATC TGG CTC
 Leu Leu Val Phe Leu Cys Thr Phe Met Gln Ile Val Ile Cys Val Ile Trp Leu>
 TAC ACC GCG CCC CCC TCA AGC TAC CGC AAC CAG GAG CTG GAG GAT GAG ATC ATC
 Tyr Thr Ala Pro Pro Ser Ser Tyr Arg Asn Gln Glu Leu Glu Asp Glu Ile Ile>
 TTC ATC ACG TGC CAC GAG GGC TCC CTC ATG GCC CTG GGC TTC CTG ATC GGC TAC
 Phe Ile Thr Cys His Glu Gly Ser Leu Met Ala Leu Gly Phe Leu Ile Gly Tyr>
 ACC TGC CTG CTG GCT GCC ATC TGC TTC TTC TTT GCC TTC AAG TCC CGG AAG CTG
 Thr Cys Leu Leu Ala Ala Ile Cys Phe Phe Phe Ala Phe Lys Ser Arg Lys Leu>
 CCG GAG AAC TTC AAT GAA GCC AAG TTC ATC ACC TTC AGC ATG CTC ATC TTC TTC
 Pro Glu Asn Phe Asn Glu Ala Lys Phe Ile Thr Phe Ser Met Leu Ile Phe Phe>
 ATC GTC TGG ATC TCC TTC ATT CCA GCC TAT GCC AGC ACC TAT GGC AAG TTT GTC
 Ile Val Trp Ile Ser Phe Ile Pro Ala Tyr Ala Ser Thr Tyr Gly Lys Phe Val>
 TCT GCC GTA GAG GTG ATT GCC ATC CTG GCA GCC AGC TTT GGC TTG CTG GCG TGC
 Ser Ala Val Glu Val Ile Ala Ile Leu Ala Ala Ser Phe Gly Leu Leu Ala Cys>
 ATC TTC TTC AAC AAG ATC TAC ATC ATT CTC TTC AAG CCA TCC CGC AAC ACC ATC
 Ile Phe Phe Asn Lys Ile Tyr Ile Ile Leu Phe Lys Pro Ser Arg Asn Thr Ile>
 GAG GAG GTG CGT TGC AGC ACC GCA GCT CAC GCT TTC AAG GTG GCT GCC CGG GCC
 Glu Glu Val Arg Cys Ser Thr Ala Ala His Ala Phe Lys Val Ala Ala Arg Ala>
 ACG CTG CGC CGC AGC AAC GTC TCC CGC AAG CGG TCC AGC AGC CTT GGA GGC TCC
 Thr Leu Arg Arg Ser Asn Val Ser Arg Lys Arg Ser Ser Ser Leu Gly Gly Ser>

FIGURE 3C

ACG GGA TCC ACC CCC TCC TCC TCC ATC AGC AGC AAG AGC AAC AGC GAA GAC CCA
 Thr Gly Ser Thr Pro Ser Ser Ser Ile Ser Ser Lys Ser Asn Ser Glu Asp Pro>
 TTC CCA CAG CCC GAG AGG CAG AAG CAG CAG CAG CCG CTG GCC CTA ACC CAG CAA
 Phe Pro Gln Pro Glu Arg Gln Lys Gln Gln Gln Pro Leu Ala Leu Thr Gln Gln>
 GAG CAG CAG CAG CAG CCC CTG ACC CTC CCA CAG CAG CAA CGA TCT CAG CAG CAG
 Glu Gln Gln Gln Gln Pro Leu Thr Leu Pro Gln Gln Gln Arg Ser Gln Gln Gln>
 CCC AGA TGC AAG CAG AAG GTC ATC TTT GGC AGC GGC ACC GTC ACC TTC TCA CTG
 Pro Arg Cys Lys Gln Lys Val Ile Phe Gly Ser Gly Thr Val Thr Phe Ser Leu>
 AGC TTT GAT GAG CCT CAG AAG AAC GCC ATG GCC CAC GGC AAT TCT ACG CAC CAG
 Ser Phe Asp Glu Pro Gln Lys Asn Ala Met Ala His Gly Asn Ser Thr His Gln>
 AAC TCC CTG GAG GCC CAG AAA AGC AGC GAT ACG CTG ACC CGA CAC CAG CCA TTA
 Asn Ser Leu Glu Ala Gln Lys Ser Ser Asp Thr Leu Thr Arg His Gln Pro Leu>
 CTC CCG CTG CAG TGC GGG GAA ACG GAC TTA GAT CTG ACC GTC CAG GAA ACA GGT
 Leu Pro Leu Gln Cys Gly Glu Thr Asp Leu Asp Leu Thr Val Gln Glu Thr Gly>
 CTG CAA GGA CCT GTG GGT GGA GAC CAG CGC CCA GAG GTG GAG GAC CCT GAA GAG
 Leu Gln Gly Pro Val Gly Gly Asp Gln Arg Pro Glu Val Glu Asp Pro Glu Glu>
 TTG TCC CCA GCA CTT GTA GTG TCC AGT TCA CAG AGC TTT GTC ATC AGT GGT GGA
 Leu Ser Pro Ala Leu Val Val Ser Ser Ser Gln Ser Phe Val Ile Ser Gly Gly>
 GGC AGC ACT GTT ACA GAA AAC GTA GTG AAT TCA
 Gly Ser Thr Val Thr Glu Asn Val Val Asn Ser>

FIGURE 3D

FIGURE 4



SEQUENCE LISTING

<110> NPS PHARMACEUTICALS, INC.

<120> NOVEL GABA_B RECEPTOR

<130> 241/143-PCT

<140> TO BE ASSIGNED

<141> 199-04-02

<150> US 60/080,676

<151> 1998-04-03

<160> 9

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 2823

<212> DNA

<213> Human

<400> 1

atggcttccc	cgcgagctc	cgggcagccc	gggcccgcgc	cgccgcgcgc	accgcccgc	60
gcgcgcctgc	tactgctact	gtgctgccc	ctgctgctgc	ctctggcgcc	cggggcctgg	120
ggctgggcgc	ggggcgcccc	ccggccgcgc	cccagcagcc	cgccgctctc	catcatgggc	180
ctcatgcgc	tcaccaagga	ggtggccaag	ggcagcatcg	ggcgcggtgt	gtccccgc	240
gtggaactgg	ccatcgagca	gatccgcaac	gagtcactcc	tgcgccccta	cttccctgcac	300
ctgcggtctc	atgacacgga	gtgcgacaac	gcaaaagggt	tgaaagcctt	ctacgatgca	360
ataaaatacg	ggccgaacca	cttgatggtg	tttggaggcg	tctgtccatc	cgtcacatcc	420
atcattgcag	agtcctccca	aggctggaat	ctggtgcagc	tttcttttgc	tgcaaccacg	480
cctgttctag	ccgataagaa	aaaataccct	tatttcttcc	ggaccgtccc	atcagacaat	540
gcggtgaatc	cagccattct	gaagttgctc	aagcactacc	agtgggaagcg	cgtgggcacg	600
ctgacgcaag	acgttcagag	gttctctgag	gtgcggaatg	acctgactgg	agttctgtat	660
ggcgaggaca	ttgagatttc	agacaccgag	agcttctcca	acgatccctg	taccagtgtc	720
aaaaagctga	aggggaatga	tgtgcggtac	atccttgggc	agtttgacca	gaatatggca	780
gcaaaagtgt	tctgttgtgc	atacgaggag	aacatgtatg	gtagtaaata	tcagtggatc	840
attccgggct	ggtacgagcc	ttcttggtgg	gagcaggtgc	acacggaagc	caactcatcc	900
cgctgcctcc	ggaagaatct	gcttgctgcc	atggagggct	acattggcgt	ggatttcgag	960
cccctgagct	ccaagcagat	caagaccatc	tcaggaaaaga	ctccacagca	gtatgagaga	1020
gagtacaaca	acaagcggtc	aggcgtgggg	cccagcaagt	tcacagggtg	cgccctacgat	1080
ggcatctggg	tcacgcgcaa	gacactgcag	agggccatgg	agacactgca	tgccagcagc	1140
cggcaccagc	ggatccagga	cttcaactac	acggaccaca	cgctgggcag	gatcatcctc	1200
aatgccatga	acgagaccaa	cttcttcggg	gtcacgggtc	aagttgtatt	ccggaatggg	1260
gagagaatgg	ggaccattaa	atttactcaa	tttcaagaca	gcagggaggt	gaaggtggga	1320
gagtacaacg	ctgtggccga	cacactggag	atcatcaatg	acaccatcag	gttccaagga	1380
tcggaaccac	caaaagacaa	gaccatcatc	ctggagcagc	tgcggaagat	ctccctacct	1440
ctctacagca	tcctctctgc	cctcaccatc	ctcgggatga	tcattggccag	tgcttttctc	1500

ttctttcaaca	tcaagaaccg	gaatcagaag	ctcataaaga	tgtcgagtcc	atacatgaac	1560
aaccttatca	tccttggagg	gatgctctcc	tatgcttcca	tatttctctt	tggccttgat	1620
ggatcccttg	tctctgaaaa	gacctttgaa	acactttgca	ccgtcaggac	ctggattctc	1680
accgtgggct	acacgaccgc	ttttggggcc	atgtttgcaa	agacctggag	agtccacgcc	1740
atcttcaaaa	atgtgaaaat	gaagaagaag	atcatcaagg	accagaaact	gcttgtgatc	1800
gtggggggca	tgtctgctgat	cgacctgtgt	atcctgatct	gctggcaggc	tgtggacccc	1860
ctgcgaagga	cagtggagaa	gtacagcatg	gagccggacc	cagcaggacg	ggatatctcc	1920
atccgccctc	tcctggagca	ctgtgagaac	acccatatga	ccatctggct	tggcatcgtc	1980
tatgcctaca	agggacttct	catgttgttc	ggttgtttct	tagcttggga	gacccgcaac	2040
gtcagcatcc	ccgcactcaa	cgacagcaag	tacatcggga	tgagtgtcta	caacgtgggg	2100
atcatgtgca	tcacgggggc	cgctgtctcc	ttcctgaccc	gggaccagcc	caatgtgcag	2160
ttctgcatcg	tggctctggg	catcatcttc	tgcagcacca	tcacctctg	cctgggtattc	2220
gtgccgaagc	tcataccctc	gagaacaaac	ccagatgcag	caacgcagaa	caggcgattc	2280
cagttcactc	agaatcagaa	gaaagaagat	tctaaaacgt	ccacctcggt	caccagtgtg	2340
aaccaagcca	gcacatcccg	cctggagggc	ctacagtcag	aaaaccatcg	cctgcgaatg	2400
aagatcacag	agctggataa	agacttgga	gaggtcacca	tgcagctgca	ggacacacca	2460
gaaaagacca	cctacattaa	acagaaccac	taccaagagc	tcaatgacat	cctcaacctg	2520
gtgaaacttca	ctgagagcac	agatggagga	aaggccattt	taaaaaatca	cctcgatcaa	2580
aatccccagc	tacagtggaa	cacaacagag	ccctctcgaa	catgcaaaga	tcctatagaa	2640
gatataaact	ctccagaaca	catccagcgt	cggctgtccc	tccagctccc	catcctccac	2700
cacgcctacc	tcccatccat	cggaggcgtg	gacgccagct	gtgtcagccc	ctgcgtcagc	2760
cccacgccca	gccccgcgca	cagacatgtg	ccacctcct	tccgagtcac	ggtctcgggc	2820
ctg						2823

<210> 2
 <211> 3464
 <212> DNA
 <213> Human

<400> 2

atgttgctgc	tgtctgtact	ggcgccactc	ttcctccgcc	ccccggggcg	gggccccggc	60
cagaccccc	acgccacetc	agaaggttgc	cagatcatac	acccgcctcg	ggaagggggc	120
atcaggtacc	ggggcctgac	tcgggaccag	gtgaaggcta	tcaacttcct	gccagtgga	180
tatgagattg	agtatgtgtg	ccggggggag	cgcgaggtgg	tggggcccaa	ggtccgcaag	240
tgcctggcca	acggctcctg	gacagatatg	gacacaccca	gccgctgtgt	ccgaatctgc	300
tccaagtctt	atctgacctt	ggaaaatggg	aaggttttcc	tgcagggtgg	ggacctccca	360
gctctggagc	gagccccggg	ggatttccgg	tgtgaccccc	acttccatct	ggtgggcagc	420
tcccggagca	tctgtagtca	gggcccagtg	agcaccccc	agccccactg	ccaggtgaat	480
cgaacgccac	actcagaacg	gcgcgcagtg	tacatcgggg	cactgtttcc	catgagcggg	540
ggctggccag	ggggccaggc	ctgccagccc	gcggtggaga	tggcgttgga	ggacgtgaat	600
agccgcaggg	acatcctgcc	ggactatgag	ctcaagctca	tccaccacga	cagcaagtgt	660
gatccaggcc	aagccaccaa	gtacctatat	gagctgctct	acaacgacct	tatcaagatc	720
atccttatgc	ctggctgcag	ctctgtctcc	acgctgggtg	ctgaggctgc	taggatgtgg	780
aacctcattg	tgttttccca	tggctccagc	tcaccagccc	tgtcaaaccg	gcagcgtttc	840
cccactttct	tccgaacgca	cccatacgcc	acactccaca	acctaccgg	cgtgaaactc	900
tttgaaaagt	ggggctggaa	gaagattgct	accatccagc	agaccactga	ggtcttctct	960
togactctgg	acgacctgga	ggaacgagtg	aaggaggctg	gaattgagat	tactttccgc	1020
cagagtttct	tctcagatcc	agctgtgccc	gtcaaaaacc	tgaagcgcca	ggatgcccga	1080
atcatcgtgg	gacttttcta	tgcagactgaa	gcccggaag	ttttttgtga	ggtgtacaag	1140
gagcgtctct	ttgggaagaa	gtacgtctgg	ttcctcattg	ggtgggtatg	tgacaattgg	1200
ttcaagatct	acgaccttcc	tatcaactgc	acagtggatg	agatgactga	ggcgggtggg	1260
ggccacatca	caactgagat	tgtcatgctg	aatcctgcca	ataccgcag	catttccaac	1320
atgacatccc	aggaatttgt	ggagaaacta	accaagcgac	tgaagagaca	ccctgaggag	1380
acaggaggct	tccaggaggc	accgctggcc	tatgatgcca	tctgggcctt	ggcactggcc	1440
ctgaacaaga	catctggagg	aggcggccgt	tctggtgtgc	gcctggaggga	cttcaactac	1500

aacaaccaga	ccattaccga	ccaaatctac	cgggcaatga	actcttcgtc	ctttgagggg	1560
gtctctggcc	atgtgggtgt	tgatgccagc	ggctctcgga	tggcatggac	gcttatcgag	1620
cagcttcagg	gtggcagcta	caagaagatt	ggctactatg	acagcaccaa	ggatgatctt	1680
tcctgggtcca	aaacagataa	atggattgga	gggtccccc	cagctgacca	gacctgggtc	1740
atcaagacat	tcgcttccct	gtcacagaaa	ctctttatct	ccgtctcagt	tctctccagc	1800
ctgggcatg	tcctagctgt	tgtctgtctg	tcctttaaca	tctacaactc	acatgtccgt	1860
tatatccaga	actcacagcc	caacctgaac	aacctgactg	ctgtgggctg	ctcatcggt	1920
ttagctgctg	tcttccccct	ggggctcgat	ggttaccaca	ttgggaggaa	ccagtttccct	1980
ttcgtctgcc	aggccccgct	ctggctcctg	ggcctgggct	ttagtctggg	ctacggttcc	2040
atgttcacca	agatttggtg	ggtcacacag	gtcttcacaa	agaaggaa	aaagaaggag	2100
tggaggaa	ctctggaacc	ctggaagctg	tatgccacag	tgggcctgct	gggtgggcatg	2160
gatgtctca	ctctcgccat	ctggcagatc	gtggaccctc	tgcaccggac	cattgagaca	2220
tttgccaagg	aggaacctaa	ggaagatatt	gacgtctcta	ttctgcccc	gctggagcat	2280
tgcagctcca	ggaagatgaa	tacatggctt	ggcattttct	atggttataa	ggggctgctg	2340
ctgtgctgg	gaatcttcc	tgcttatgag	accaagagt	tgtccactga	gaagatcaat	2400
gatcacccgg	ctgtgggcat	ggctatctac	aatgtggcag	tcctgtgcct	catcactgct	2460
cctgtacca	tgattctgtc	cagccagcag	gatgcagcct	ttgcctttgc	ctctcttgcc	2520
atagttttct	cctcctatat	cactcttgtt	gtgctctttg	tgcccaagat	gcgcaggctg	2580
atcacccgag	gggaatggca	gtcggaggcg	caggacacca	tgaagacagg	gtcatcgacc	2640
aacaacaacg	aggaggagaa	gtcccggctg	ttggagaagg	agaaccgtga	actggaaaag	2700
atcattgctg	agaaaagagg	gcgtgtctct	gaactgcgcc	atcagctcca	gtctcggcag	2760
cagctccgct	cccggcgcca	cccaccgaca	cccccagaac	cctctggggg	cctgcccagg	2820
ggacccccctg	agccccccga	ccggcttagc	tgtgatggga	gtcagatgca	tttgctttat	2880
aagtgaggg	aggggtgagg	aggacaggcc	agtaggggga	gggaaaaggga	gagggggaagg	2940
gcaggggact	caggaagcag	gggggtccca	tcccagctg	ggaagaacat	gctatccaat	3000
ctcatctctt	gtaaatacat	gtccccctgt	gagttctggg	ctgatttggg	tctctcatac	3060
ctctgggaaa	cagacctttt	tctctcttac	tgcttcatgt	aattttgtat	cacctcttca	3120
caatttagtt	cgtacctggc	ttgaagctgc	tcactgtctc	cacgtgcct	cctcagcagc	3180
ctcactgcat	ctttctcttc	ccatgcaaca	ccctcttcta	gttaccacgg	caacccttgc	3240
agctcctctg	cctttgtgct	ctgttctgt	ccagcagggg	tctccaaca	agtgtctttt	3300
ccaccccaaa	ggggcctctc	cttttctcca	ctgtcataat	ctctttccat	cttacttgcc	3360
cttctatact	ttctcacatg	tggtccccc	tgaattttgc	ttcctttggg	gagctcattc	3420
ntttcgccaa	ggntcacatg	ctcccttgcc	tctggctccg	tgca		3464

<210> 3

<211> 2887

<212> DNA

<213> Human

<400> 3

atggggcccg	gggccccttt	tgcccgggtg	gggtggccac	tgccgcttct	ggttgtgatg	60
gcggcagggg	tggctccggg	gtgggcctcc	cactccccc	atctcccgg	gcctcactcg	120
cgggtccccc	cgcaccctc	ctcagaacgg	cgcgcagtgt	acatcgggg	actgtttccc	180
atgagcgggg	gctggccagg	gggccaggcc	tgccagccc	cgggtggagat	ggcgtgggag	240
gacgtgaata	gccgcaggga	catcctgccg	gactatgagc	tcaagctcat	ccaccacgac	300
agcaagtgtg	atccaggcca	agccaccaag	tacctatatg	agctgtctta	caacgacct	360
atcaagatca	tccttatgcc	tggtgcagc	tctgtctcca	cgtgggtggc	tgaggtgct	420
aggatgtgga	acctcattgt	gctttcctat	ggctccagct	caccagccct	gtcaaacccg	480
cagcgtttcc	ccactttctt	ccgaacgcac	ccatcagcca	cactccacaa	ccctaccgc	540
gtgaaactct	ttgaaaagt	gggctggaag	aagattgcta	ccatccagca	gaccactgag	600
gtcttcactt	cgactctgga	cgacctggag	gaacgagtga	aggaggctgg	aattgagatt	660
actttccgcc	agagtttctt	ctcagatcca	gctgtgccc	tcaaaaacct	gaagcgccag	720
gatgcccga	tcatcgtggg	acttttctat	gagactgaag	cccggaaagt	ttttgtgag	780
gtgtacaagg	agcgtctctt	tgggaagaag	tacgtctgg	tcctcattgg	gtgggatgct	840
gacaattgg	tcaagatcta	cgaccttct	atcaactgca	cagtggatga	gatgactgag	900


```

gcggtggagg gccacatcac aactgagatt gtcattgctga atcctgccaa taccgcgagc 960
atttccaaca tgacatccca ggaattttgtg gagaaactaa ccaagcgact gaaaagacac 1020
cctgaggaga caggaggcct ccaggaggca ccgctggcct atgatgccat ctgggccttg 1080
gcactggccc tgaacaagac atctggagga ggcggccgtt ctggtgtgcg cctggaggac 1140
ttcaactaca acaaccagac cattaccgac caaatctacc gggcaatgaa ctcttcgtcc 1200
tttgaggggtg tctctggcca tgtggtgttt gatgccagcg gctctcggat ggcattggacg 1260
cttatcgagc agcttcaggg tggcagctac aagaagattg gctactatga cagcaccaag 1320
gatgatcttt cctgggtccaa aacagataaa tggattggag ggtccccccc agctgaccag 1380
accctgggtca tcaagacatt ccgcttcctg tcacagaaac tctttatctc cgtctcagtt 1440
ctctccagcc tgggcattgt cctagctgtt gtctgtctgt cctttaacat ctacaactca 1500
catgtccgtt atatccagaa ctcacagccc aacctgaaca acctgactgc tgtgggctgc 1560
tcactggctt tagctgctgt cttccccctg gggctcgtat gttaccacat tgggaggaac 1620
cagtttctct tcgtctgcca ggcccgcctc tggctcctgg gcctgggctt tagtctgggc 1680
tacggttcca tgttcaccaa gatttggtgg gtccacacgg tcttcacaaa gaaggaagaa 1740
aagaaggagt ggaggaagac tctggaaccc tgggaagctgt atgccacagt gggcctgctg 1800
gtgggcatgg atgtcctcac tctcgccatc tggcagatcg tggaccctct gcaccggacc 1860
attgagacat ttgccaaagg ggaacctaaag gaagatattg acgtctctat tctgccccag 1920
ctggagcatt gcagctccag gaagatgaat acatggcttg gcattttcta tggttacaag 1980
gggctgctgc tgctgctggg aatcttcctt gcttatgaga ccaagagtgt gtccactgag 2040
aagatcaatg atcaccgggc tgtgggcatg gctatctaca atgtggcagt cctgtgcctc 2100
atcactgtct ctgtcaccat gattctgtcc agccagcagg atgcagcctt tgcctttgcc 2160
tctcttgcca tagttttctc ctctatatc actcttgttg tgctctttgt gcccaagatg 2220
cgcaggctga tcacccgagg ggaatggcag tcggaggcgc aggacaccat gaagacaggg 2280
tcactgacca acaacaacga ggaggagaag tcccggctgt tggagaagga gaaccgtgaa 2340
ctggaaaaga tcattgctga gaaagaggag cgtgtctctg aactgcgcca tcaactccag 2400
tctcggcagc agctccgctc ccggcgccac ccaccgacac cccagaaacc ctctgggggc 2460
ctgcccaggg gacccctga gcccccgac cggcttagct gtgatgggag tcgagtgcac 2520
ttgctttata agtgaggta gggtgaggga ggacaggcca gtagggggag ggaagggag 2580
aggggaaggg caggggactc aggaagcagg ggggtcccat cccagctgg gaagaacatg 2640
ctatccaatc tcatctcttg taaatacatg tccccctgtg agttctgggc tgatttgggt 2700
ctctcatacc tctgggaaac agacctttt ctctcttact gcttcattga attttgtatc 2760
acctcttcac aatttagttc gtacctggct tgaagctgct cactgctcac acgctgcctc 2820
ctcagcagcc tcactgcac tttctcttcc catgcaacac cctcttctag ttaccacggc 2880
aaccct

```

<210> 4

<211> 943

<212> PRT

<213> Human

<400> 4

```

Met Ala Ser Pro Arg Ser Ser Gly Gln Pro Gly Pro Xaa Pro Pro Pro
1           5           10           15

Pro Pro Pro Pro Ala Arg Leu Leu Leu Leu Leu Leu Pro Leu Leu
20           25           30

Leu Pro Leu Ala Pro Gly Ala Trp Gly Trp Ala Arg Gly Ala Pro Arg
35           40           45

Pro Pro Pro Ser Ser Pro Pro Leu Ser Ile Met Gly Leu Met Pro Leu
50           55           60

```

Thr Lys Glu Val Ala Lys Gly Ser Ile Gly Arg Gly Val Leu Pro Ala
 65 70 75 80
 Val Glu Leu Ala Ile Glu Gln Ile Arg Asn Glu Ser Leu Leu Arg Pro
 85 90 95
 Tyr Phe Leu Asp Leu Arg Leu Tyr Asp Thr Glu Cys Asp Asn Ala Lys
 100 105 110
 Gly Leu Lys Ala Phe Tyr Asp Ala Ile Lys Tyr Gly Pro Asn His Leu
 115 120 125
 Met Val Phe Gly Gly Val Cys Pro Ser Val Thr Ser Ile Ile Ala Glu
 130 135 140
 Ser Leu Gln Gly Trp Asn Leu Val Gln Leu Ser Phe Ala Ala Thr Thr
 145 150 155 160
 Pro Val Leu Ala Asp Lys Lys Lys Tyr Pro Tyr Phe Phe Arg Thr Val
 165 170 175
 Pro Ser Asp Asn Ala Val Asn Pro Ala Ile Leu Lys Leu Leu Lys His
 180 185 190
 Tyr Gln Trp Lys Arg Val Gly Thr Leu Thr Gln Asp Val Gln Arg Phe
 195 200 205
 Ser Glu Val Arg Asn Asp Leu Thr Gly Val Leu Tyr Gly Glu Asp Ile
 210 215 220
 Glu Ile Ser Asp Thr Glu Ser Phe Ser Asn Asp Pro Cys Thr Ser Val
 225 230 235 240
 Lys Lys Leu Lys Gly Asn Asp Val Arg Ile Ile Leu Gly Gln Phe Asp
 245 250 255
 Gln Asn Met Ala Ala Lys Val Phe Cys Cys Ala Tyr Glu Glu Asn Met
 260 265 270
 Tyr Gly Ser Lys Tyr Gln Trp Ile Ile Pro Gly Trp Tyr Glu Pro Ser
 275 280 285
 Trp Trp Glu Gln Val His Thr Glu Ala Asn Ser Ser Arg Cys Leu Arg
 290 295 300
 Lys Asn Leu Leu Ala Ala Met Glu Gly Tyr Ile Gly Val Asp Phe Glu
 305 310 315 320
 Pro Leu Ser Ser Lys Gln Ile Lys Thr Ile Ser Gly Lys Thr Pro Gln
 325 330 335
 Gln Tyr Glu Arg Glu Tyr Asn Asn Lys Arg Ser Gly Val Gly Pro Ser
 340 345 350
 Lys Phe His Gly Tyr Ala Tyr Asp Gly Ile Trp Val Ile Ala Lys Thr
 355 360 365

Leu Gln Arg Ala Met Glu Thr Leu His Ala Ser Ser Arg His Gln Arg
 370 375 380
 Ile Gln Asp Phe Asn Tyr Thr Asp His Thr Leu Gly Arg Ile Ile Leu
 385 390 395 400
 Asn Ala Met Asn Glu Thr Asn Phe Phe Gly Val Thr Gly Gln Val Val
 405 410 415
 Phe Arg Asn Gly Glu Arg Met Gly Thr Ile Lys Phe Thr Gln Phe Gln
 420 425 430
 Asp Ser Arg Glu Val Lys Val Gly Glu Tyr Asn Ala Val Ala Asp Thr
 435 440 445
 Leu Glu Ile Ile Asn Asp Thr Ile Arg Phe Gln Gly Ser Glu Pro Pro
 450 455 460
 Lys Asp Lys Thr Ile Ile Leu Glu Gln Leu Arg Lys Ile Ser Leu Pro
 465 470 475 480
 Leu Tyr Ser Ile Leu Ser Ala Leu Thr Ile Leu Gly Met Ile Met Ala
 485 490 495
 Ser Ala Phe Leu Phe Phe Asn Ile Lys Asn Arg Asn Gln Lys Leu Ile
 500 505 510
 Lys Met Ser Ser Pro Tyr Met Asn Asn Leu Ile Ile Leu Gly Gly Met
 515 520 525
 Leu Ser Tyr Ala Ser Ile Phe Leu Phe Gly Leu Asp Gly Ser Phe Val
 530 535 540
 Ser Glu Lys Thr Phe Glu Thr Leu Cys Thr Val Arg Thr Trp Ile Leu
 545 550 555 560
 Thr Val Gly Tyr Thr Thr Ala Phe Gly Ala Met Phe Ala Lys Thr Trp
 565 570 575
 Arg Val His Ala Ile Phe Lys Asn Val Lys Met Lys Lys Lys Ile Ile
 580 585 590
 Lys Asp Gln Lys Leu Leu Val Ile Val Gly Gly Met Leu Leu Ile Asp
 595 600 605
 Leu Cys Ile Leu Ile Cys Trp Gln Ala Val Asp Pro Leu Arg Arg Thr
 610 615 620
 Val Glu Lys Tyr Ser Met Glu Pro Asp Pro Ala Gly Arg Asp Ile Ser
 625 630 635 640
 Ile Arg Pro Leu Leu Glu His Cys Glu Asn Thr His Met Thr Ile Trp
 645 650 655
 Leu Gly Ile Val Tyr Ala Tyr Lys Gly Leu Leu Met Leu Phe Gly Cys
 660 665 670

7

Phe Leu Ala Trp Glu Thr Arg Asn Val Ser Ile Pro Ala Leu Asn Asp
 675 680 685
 Ser Lys Tyr Ile Gly Met Ser Val Tyr Asn Val Gly Ile Met Cys Ile
 690 695 700
 Ile Gly Ala Ala Val Ser Phe Leu Thr Arg Asp Gln Pro Asn Val Gln
 705 710 715 720
 Phe Cys Ile Val Ala Leu Val Ile Ile Phe Cys Ser Thr Ile Thr Leu
 725 730 735
 Cys Leu Val Phe Val Pro Lys Leu Ile Thr Leu Arg Thr Asn Pro Asp
 740 745 750
 Ala Ala Thr Gln Asn Arg Arg Phe Gln Phe Thr Gln Asn Gln Lys Lys
 755 760 765
 Glu Asp Ser Lys Thr Ser Thr Ser Val Thr Ser Val Asn Gln Ala Ser
 770 775 780
 Thr Ser Arg Leu Glu Gly Leu Gln Ser Glu Asn His Arg Leu Arg Met
 785 790 795 800
 Lys Ile Thr Glu Leu Asp Lys Asp Leu Glu Glu Val Thr Met Gln Leu
 805 810 815
 Gln Asp Thr Pro Glu Lys Thr Thr Tyr Ile Lys Gln Asn His Tyr Gln
 820 825 830
 Glu Leu Asn Asp Ile Leu Asn Leu Gly Asn Phe Thr Glu Ser Thr Asp
 835 840 845
 Gly Gly Lys Ala Ile Leu Lys Asn His Leu Asp Gln Asn Pro Gln Leu
 850 855 860
 Gln Trp Asn Thr Thr Glu Pro Ser Arg Thr Cys Lys Asp Pro Ile Glu
 865 870 875 880
 Asp Ile Asn Ser Pro Glu His Ile Gln Arg Arg Leu Ser Leu Gln Leu
 885 890 895
 Pro Ile Leu His His Ala Tyr Leu Pro Ser Ile Gly Gly Val Asp Ala
 900 905 910
 Ser Cys Val Ser Pro Cys Val Ser Pro Thr Ala Ser Pro Arg His Arg
 915 920 925
 His Val Pro Pro Ser Phe Arg Val Met Val Ser Gly Leu Ser Asp
 930 935 940

<210> 5
 <211> 960
 <212> PRT
 <213> Rat

<400> 5

Met Leu Leu Leu Leu Val Pro Leu Phe Leu Arg Pro Leu Gly Ala
 1 5 10 15
 Gly Gly Ala Gln Thr Pro Asn Ala Thr Ser Glu Gly Cys Gln Ile Ile
 20 25 30
 His Pro Pro Trp Glu Gly Gly Ile Arg Tyr Arg Gly Leu Thr Arg Asp
 35 40 45
 Gln Val Lys Ala Ile Asn Phe Leu Pro Val Asp Tyr Glu Ile Glu Tyr
 50 55 60
 Val Cys Arg Gly Glu Arg Glu Val Val Gly Pro Lys Val Arg Lys Cys
 65 70 75 80
 Leu Ala Asn Gly Ser Trp Thr Asp Met Asp Thr Pro Ser Arg Cys Val
 85 90 95
 Arg Ile Cys Ser Lys Ser Tyr Leu Thr Leu Glu Asn Gly Lys Val Phe
 100 105 110
 Leu Thr Gly Gly Asp Leu Pro Ala Leu Asp Gly Ala Arg Val Glu Phe
 115 120 125
 Arg Cys Asp Pro Asp Phe His Leu Val Gly Ser Ser Arg Ser Val Cys
 130 135 140
 Ser Gln Gly Gln Trp Ser Thr Pro Lys Pro His Cys Gln Val Asn Arg
 145 150 155 160
 Thr Pro His Ser Glu Arg Arg Ala Val Tyr Ile Gly Ala Leu Phe Pro
 165 170 175
 Met Ser Gly Gly Trp Pro Gly Gly Gln Ala Cys Gln Pro Ala Val Glu
 180 185 190
 Met Ala Leu Glu Asp Val Asn Ser Arg Arg Asp Ile Leu Pro Asp Tyr
 195 200 205
 Glu Leu Lys Leu Ile His His Asp Ser Lys Cys Asp Pro Gly Gln Ala
 210 215 220
 Thr Lys Tyr Leu Tyr Glu Leu Leu Tyr Asn Asp Pro Ile Lys Ile Ile
 225 230 235 240
 Leu Met Pro Gly Cys Ser Ser Val Ser Thr Leu Val Ala Glu Ala Ala
 245 250 255
 Arg Met Trp Asn Leu Ile Val Leu Ser Tyr Gly Ser Ser Ser Pro Ala
 260 265 270
 Leu Ser Asn Arg Gln Arg Phe Pro Thr Phe Phe Arg Thr His Pro Ser
 275 280 285
 Ala Thr Leu His Asn Pro Thr Arg Val Lys Leu Phe Glu Lys Trp Gly
 290 295 300

Trp Lys Lys Ile Ala Thr Ile Gln Gln Thr Thr Glu Val Phe Thr Ser
 305 310 315 320
 Thr Leu Asp Asp Leu Glu Glu Arg Val Lys Glu Ala Gly Ile Glu Ile
 325 330 335
 Thr Phe Arg Gln Ser Phe Phe Ser Asp Pro Ala Val Pro Val Lys Asn
 340 345 350
 Leu Lys Arg Gln Asp Ala Arg Ile Ile Val Gly Leu Phe Tyr Glu Thr
 355 360 365
 Glu Ala Arg Lys Val Phe Cys Glu Val Tyr Lys Glu Arg Leu Phe Gly
 370 375 380
 Lys Lys Tyr Val Trp Phe Leu Ile Gly Trp Tyr Ala Asp Asn Trp Phe
 385 390 395 400
 Lys Thr Tyr Asp Pro Ser Ile Asn Cys Thr Val Glu Glu Met Thr Glu
 405 410 415
 Ala Val Glu Gly His Ile Thr Thr Glu Ile Val Met Leu Asn Pro Ala
 420 425 430
 Asn Thr Arg Ser Ile Ser Asn Met Thr Ser Gln Glu Phe Val Glu Lys
 435 440 445
 Leu Thr Lys Arg Leu Lys Arg His Pro Glu Glu Thr Gly Gly Phe Gln
 450 455 460
 Glu Ala Pro Leu Ala Tyr Asp Ala Ile Trp Ala Leu Ala Leu Ala Leu
 465 470 475 480
 Asn Lys Thr Ser Gly Gly Gly Gly Arg Ser Gly Val Arg Leu Glu Asp
 485 490 495
 Phe Asn Tyr Asn Asn Gln Thr Ile Thr Asp Gln Ile Tyr Arg Ala Met
 500 505 510
 Asn Ser Ser Ser Phe Glu Gly Val Ser Gly His Val Val Phe Asp Ala
 515 520 525
 Ser Gly Ser Arg Met Ala Trp Thr Leu Ile Glu Gln Leu Gln Gly Gly
 530 535 540
 Ser Tyr Lys Lys Ile Gly Tyr Tyr Asp Ser Thr Lys Asp Asp Leu Ser
 545 550 555 560
 Trp Ser Lys Thr Asp Lys Trp Ile Gly Gly Ser Pro Pro Ala Asp Gln
 565 570 575
 Ile Leu Val Ile Lys Thr Phe Arg Phe Leu Ser Gln Lys Leu Phe Ile
 580 585 590
 Ser Val Ser Val Leu Ser Ser Leu Gly Ile Val Leu Ala Val Val Cys
 595 600 605

10

Leu Ser Phe Asn Ile Tyr Asn Ser His Val Arg Tyr Ile Gln Asn Ser
 610 615 620
 Gln Pro Asn Leu Asn Asn Leu Thr Ala Val Gly Cys Ser Leu Ala Leu
 625 630 635 640
 Ala Ala Val Phe Pro Leu Gly Leu Asp Gly Tyr His Ile Gly Arg Ser
 645 650 655
 Gln Phe Pro Phe Val Cys Gln Ala Arg Leu Trp Leu Leu Gly Leu Gly
 660 665 670
 Phe Ser Leu Gly Tyr Gly Ser Met Phe Thr Lys Ile Trp Trp Val His
 675 680 685
 Thr Val Phe Thr Lys Lys Glu Glu Lys Lys Glu Trp Arg Lys Thr Leu
 690 695 700
 Glu Pro Trp Lys Leu Tyr Ala Thr Val Gly Leu Leu Val Gly Met Asp
 705 710 715 720
 Val Leu Thr Leu Ala Ile Trp Gln Ile Val Asp Pro Leu His Arg Thr
 725 730 735
 Ile Glu Thr Phe Ala Lys Glu Glu Pro Lys Glu Asp Ile Asp Val Ser
 740 745 750
 Ile Leu Pro Gln Leu Glu His Cys Ser Ser Lys Lys Met Asn Thr Trp
 755 760 765
 Leu Gly Ile Phe Tyr Gly Tyr Lys Gly Leu Leu Leu Leu Gly Ile
 770 775 780
 Phe Leu Ala Tyr Glu Thr Lys Ser Val Ser Thr Glu Lys Ile Asn Asp
 785 790 795 800
 His Arg Ala Val Gly Met Ala Ile Tyr Asn Val Ala Val Leu Cys Leu
 805 810 815
 Ile Thr Ala Pro Val Thr Met Ile Leu Ser Ser Gln Gln Asp Ala Ala
 820 825 830
 Phe Ala Phe Ala Ser Leu Ala Ile Val Phe Ser Ser Tyr Ile Thr Leu
 835 840 845
 Val Val Leu Phe Val Pro Lys Met Arg Arg Leu Ile Thr Arg Gly Glu
 850 855 860
 Trp Gln Ser Glu Thr Gln Asp Thr Met Lys Thr Gly Ser Ser Thr Asn
 865 870 875 880
 Asn Asn Glu Glu Glu Lys Ser Arg Leu Leu Glu Lys Glu Asn Arg Glu
 885 890 895
 Leu Glu Lys Ile Ile Ala Glu Lys Glu Glu Arg Val Ser Glu Leu Arg
 900 905 910

11

His Gln Leu Gln Ser Arg Gln Gln Leu Arg Ser Arg Arg His Pro Pro
 915 920 925

Thr Pro Pro Asp Pro Ser Gly Gly Leu Pro Arg Gly Pro Ser Glu Pro
 930 935 940

Pro Asp Arg Leu Ser Cys Asp Gly Ser Arg Val His Leu Leu Tyr Lys
 945 950 955 960

<210> 6
 <211> 844
 <212> PRT
 <213> Rat

<400> 6

Met Gly Pro Gly Gly Pro Cys Thr Pro Val Gly Trp Pro Leu Pro Leu
 1 5 10 15

Leu Leu Val Met Ala Ala Gly Val Ala Pro Val Trp Ala Ser His Ser
 20 25 30

Pro His Leu Pro Arg Pro His Pro Arg Val Pro Pro His Pro Ser Ser
 35 40 45

Glu Arg Arg Ala Val Tyr Ile Gly Ala Leu Phe Pro Met Ser Gly Gly
 50 55 60

Trp Pro Gly Gly Gln Ala Cys Gln Pro Ala Val Glu Met Ala Leu Glu
 65 70 75 80

Asp Val Asn Ser Arg Arg Asp Ile Leu Pro Asp Tyr Glu Leu Lys Leu
 85 90 95

Ile His His Asp Ser Lys Cys Asp Pro Gly Gln Ala Thr Lys Tyr Leu
 100 105 110

Tyr Glu Leu Leu Tyr Asn Asp Pro Ile Lys Ile Ile Leu Met Pro Gly
 115 120 125

Cys Ser Ser Val Ser Thr Leu Val Ala Glu Ala Ala Arg Met Trp Asn
 130 135 140

Leu Ile Val Leu Ser Tyr Gly Ser Ser Ser Pro Ala Leu Ser Asn Arg
 145 150 155 160

Gln Arg Phe Pro Thr Phe Phe Arg Thr His Pro Ser Ala Thr Leu His
 165 170 175

Asn Pro Thr Arg Val Lys Leu Phe Glu Lys Trp Gly Trp Lys Lys Ile
 180 185 190

Ala Thr Ile Gln Gln Thr Thr Glu Val Phe Thr Ser Thr Leu Asp Asp
 195 200 205

12

Leu Glu Glu Arg Val Lys Glu Ala Gly Ile Glu Ile Thr Phe Arg Gln
 210 215 220
 Ser Phe Phe Ser Asp Pro Ala Val Pro Val Lys Asn Leu Lys Arg Gln
 225 230 235 240
 Asp Ala Arg Ile Ile Val Gly Leu Phe Tyr Glu Thr Glu Ala Arg Lys
 245 250 255
 Val Phe Cys Glu Val Tyr Lys Glu Arg Leu Phe Gly Lys Lys Tyr Val
 260 265 270
 Trp Phe Leu Ile Gly Trp Tyr Ala Asp Asn Trp Phe Lys Thr Tyr Asp
 275 280 285
 Pro Ser Ile Asn Cys Thr Val Glu Glu Met Thr Glu Ala Val Glu Gly
 290 295 300
 His Ile Thr Thr Glu Ile Val Met Leu Asn Pro Ala Asn Thr Arg Ser
 305 310 315 320
 Ile Ser Asn Met Thr Ser Gln Glu Phe Val Glu Lys Leu Thr Lys Arg
 325 330 335
 Leu Lys Arg His Pro Glu Glu Thr Gly Gly Phe Gln Glu Ala Pro Leu
 340 345 350
 Ala Tyr Asp Ala Ile Trp Ala Leu Ala Leu Ala Leu Asn Lys Thr Ser
 355 360 365
 Gly Gly Gly Gly Arg Ser Gly Val Arg Leu Glu Asp Phe Asn Tyr Asn
 370 375 380
 Asn Gln Thr Ile Thr Asp Gln Ile Tyr Arg Ala Met Asn Ser Ser Ser
 385 390 395 400
 Phe Glu Gly Val Ser Gly His Val Val Phe Asp Ala Ser Gly Ser Arg
 405 410 415
 Met Ala Trp Thr Leu Ile Glu Gln Leu Gln Gly Gly Ser Tyr Lys Lys
 420 425 430
 Ile Gly Tyr Tyr Asp Ser Thr Lys Asp Asp Leu Ser Trp Ser Lys Thr
 435 440 445
 Asp Lys Trp Ile Gly Gly Ser Pro Pro Ala Asp Gln Ile Leu Val Ile
 450 455 460
 Lys Thr Phe Arg Phe Leu Ser Gln Lys Leu Phe Ile Ser Val Ser Val
 465 470 475 480
 Leu Ser Ser Leu Gly Ile Val Leu Ala Val Val Cys Leu Ser Phe Asn
 485 490 495
 Ile Tyr Asn Ser His Val Arg Tyr Ile Gln Asn Ser Gln Pro Asn Leu
 500 505 510

13

Asn Asn Leu Thr Ala Val Gly Cys Ser Leu Ala Leu Ala Ala Val Phe
 515 520 525
 Pro Leu Gly Leu Asp Gly Tyr His Ile Gly Arg Ser Gln Phe Pro Phe
 530 535 540
 Val Cys Gln Ala Arg Leu Trp Leu Leu Gly Leu Gly Phe Ser Leu Gly
 545 550 555 560
 Tyr Gly Ser Met Phe Thr Lys Ile Trp Trp Val His Thr Val Phe Thr
 565 570 575
 Lys Lys Glu Glu Lys Lys Glu Trp Arg Lys Thr Leu Glu Pro Trp Lys
 580 585 590
 Leu Tyr Ala Thr Val Gly Leu Leu Val Gly Met Asp Val Leu Thr Leu
 595 600 605
 Ala Ile Trp Gln Ile Val Asp Pro Leu His Arg Thr Ile Glu Thr Phe
 610 615 620
 Ala Lys Glu Glu Pro Lys Glu Asp Ile Asp Val Ser Ile Leu Pro Gln
 625 630 635 640
 Leu Glu His Cys Ser Ser Lys Lys Met Asn Thr Trp Leu Gly Ile Phe
 645 650 655
 Tyr Gly Tyr Lys Gly Leu Leu Leu Leu Leu Gly Ile Phe Leu Ala Tyr
 660 665 670
 Glu Thr Lys Ser Val Ser Thr Glu Lys Ile Asn Asp His Arg Ala Val
 675 680 685
 Gly Met Ala Ile Tyr Asn Val Ala Val Leu Cys Leu Ile Thr Ala Pro
 690 695 700
 Val Thr Met Ile Leu Ser Ser Gln Gln Asp Ala Ala Phe Ala Phe Ala
 705 710 715 720
 Ser Leu Ala Ile Val Phe Ser Ser Tyr Ile Thr Leu Val Val Leu Phe
 725 730 735
 Val Pro Lys Met Arg Arg Leu Ile Thr Arg Gly Glu Trp Gln Ser Glu
 740 745 750
 Thr Gln Asp Thr Met Lys Thr Gly Ser Ser Thr Asn Asn Asn Glu Glu
 755 760 765
 Glu Lys Ser Arg Leu Leu Glu Lys Glu Asn Arg Glu Leu Glu Lys Ile
 770 775 780
 Ile Ala Glu Lys Glu Glu Arg Val Ser Glu Leu Arg His Gln Leu Gln
 785 790 795 800
 Ser Arg Gln Gln Leu Arg Ser Arg Arg His Pro Pro Thr Pro Pro Asp
 805 810 815

14

Pro Ser Gly Gly Leu Pro Arg Gly Pro Ser Glu Pro Pro Asp Arg Leu
 820 825 830

Ser Cys Asp Gly Ser Arg Val His Leu Leu Tyr Lys
 835 840

<210> 7
 <211> 961
 <212> PRT
 <213> Human

<400> 7

Met Leu Leu Leu Leu Leu Leu Ala Pro Leu Phe Leu Arg Pro Pro Gly
 1 5 10 15

Ala Gly Gly Ala Gln Thr Pro Asn Ala Thr Ser Glu Gly Cys Gln Ile
 20 25 30

Ile His Pro Pro Trp Glu Gly Gly Ile Arg Tyr Arg Gly Leu Thr Arg
 35 40 45

Asp Gln Val Lys Ala Ile Asn Phe Leu Pro Val Asp Tyr Glu Ile Glu
 50 55 60

Tyr Val Cys Arg Gly Glu Arg Glu Val Val Gly Pro Lys Val Arg Lys
 65 70 75 80

Cys Leu Ala Asn Gly Ser Trp Thr Asp Met Asp Thr Pro Ser Arg Cys
 85 90 95

Val Arg Ile Cys Ser Lys Ser Tyr Leu Thr Leu Glu Asn Gly Lys Val
 100 105 110

Phe Leu Thr Gly Gly Asp Leu Pro Ala Leu Asp Gly Ala Arg Val Asp
 115 120 125

Phe Arg Cys Asp Pro Asp Phe His Leu Val Gly Ser Ser Arg Ser Ile
 130 135 140

Cys Ser Gln Gly Gln Trp Ser Thr Pro Lys Pro His Cys Gln Val Asn
 145 150 155 160

Arg Thr Pro His Ser Glu Arg Arg Ala Val Tyr Ile Gly Ala Leu Phe
 165 170 175

Pro Met Ser Gly Gly Trp Pro Gly Gly Gln Ala Cys Gln Pro Ala Val
 180 185 190

Glu Met Ala Leu Glu Asp Val Asn Ser Arg Arg Asp Ile Leu Pro Asp
 195 200 205

Tyr Glu Leu Lys Leu Ile His His Asp Ser Lys Cys Asp Pro Gly Gln
 210 215 220

15

Ala Thr Lys Tyr Leu Tyr Glu Leu Leu Tyr Asn Asp Pro Ile Lys Ile
 225 230 235 240
 Ile Leu Met Pro Gly Cys Ser Ser Val Ser Thr Leu Val Ala Glu Ala
 245 250 255
 Ala Arg Met Trp Asn Leu Ile Val Leu Ser Tyr Gly Ser Ser Ser Pro
 260 265 270
 Ala Leu Ser Asn Arg Gln Arg Phe Pro Thr Phe Phe Arg Thr His Pro
 275 280 285
 Ser Ala Thr Leu His Asn Pro Thr Arg Val Lys Leu Phe Glu Lys Trp
 290 295 300
 Gly Trp Lys Lys Ile Ala Thr Ile Gln Gln Thr Thr Glu Val Phe Thr
 305 310 315 320
 Ser Thr Leu Asp Asp Leu Glu Glu Arg Val Lys Glu Ala Gly Ile Glu
 325 330 335
 Ile Thr Phe Arg Gln Ser Phe Phe Ser Asp Pro Ala Val Pro Val Lys
 340 345 350
 Asn Leu Lys Arg Gln Asp Ala Arg Ile Ile Val Gly Leu Phe Tyr Glu
 355 360 365
 Thr Glu Ala Arg Lys Val Phe Cys Glu Val Tyr Lys Glu Arg Leu Phe
 370 375 380
 Gly Lys Lys Tyr Val Trp Phe Leu Ile Gly Trp Tyr Ala Asp Asn Trp
 385 390 395 400
 Phe Lys Ile Tyr Asp Pro Ser Ile Asn Cys Thr Val Asp Glu Met Thr
 405 410 415
 Glu Ala Val Glu Gly His Ile Thr Thr Glu Ile Val Met Leu Asn Pro
 420 425 430
 Ala Asn Thr Arg Ser Ile Ser Asn Met Thr Ser Gln Glu Phe Val Glu
 435 440 445
 Lys Leu Thr Lys Arg Leu Lys Arg His Pro Glu Glu Thr Gly Gly Phe
 450 455 460
 Gln Glu Ala Pro Leu Ala Tyr Asp Ala Ile Trp Ala Leu Ala Leu Ala
 465 470 475 480
 Leu Asn Lys Thr Ser Gly Gly Gly Gly Arg Ser Gly Val Arg Leu Glu
 485 490 495
 Asp Phe Asn Tyr Asn Asn Gln Thr Ile Thr Asp Gln Ile Tyr Arg Ala
 500 505 510
 Met Asn Ser Ser Ser Phe Glu Gly Val Ser Gly His Val Val Phe Asp
 515 520 525

16

Ala Ser Gly Ser Arg Met Ala Trp Thr Leu Ile Glu Gln Leu Gln Gly
 530 535 540
 Gly Ser Tyr Lys Lys Ile Gly Tyr Tyr Asp Ser Thr Lys Asp Asp Leu
 545 550 555 560
 Ser Trp Ser Lys Thr Asp Lys Trp Ile Gly Gly Ser Pro Pro Ala Asp
 565 570 575
 Gln Thr Leu Val Ile Lys Thr Phe Arg Phe Leu Ser Gln Lys Leu Phe
 580 585 590
 Ile Ser Val Ser Val Leu Ser Ser Leu Gly Ile Val Leu Ala Val Val
 595 600 605
 Cys Leu Ser Phe Asn Ile Tyr Asn Ser His Val Arg Tyr Ile Gln Asn
 610 615 620
 Ser Gln Pro Asn Leu Asn Asn Leu Thr Ala Val Gly Cys Ser Leu Ala
 625 630 635 640
 Leu Ala Ala Val Phe Pro Leu Gly Leu Asp Gly Tyr His Ile Gly Arg
 645 650 655
 Asn Gln Phe Pro Phe Val Cys Gln Ala Arg Leu Trp Leu Leu Gly Leu
 660 665 670
 Gly Phe Ser Leu Gly Tyr Gly Ser Met Phe Thr Lys Ile Trp Trp Val
 675 680 685
 His Thr Val Phe Thr Lys Lys Glu Glu Lys Lys Glu Trp Arg Lys Thr
 690 695 700
 Leu Glu Pro Trp Lys Leu Tyr Ala Thr Val Gly Leu Leu Val Gly Met
 705 710 715 720
 Asp Val Leu Thr Leu Ala Ile Trp Gln Ile Val Asp Pro Leu His Arg
 725 730 735
 Thr Ile Glu Thr Phe Ala Lys Glu Glu Pro Lys Glu Asp Ile Asp Val
 740 745 750
 Ser Ile Leu Pro Gln Leu Glu His Cys Ser Ser Arg Lys Met Asn Thr
 755 760 765
 Trp Leu Gly Ile Phe Tyr Gly Tyr Lys Gly Leu Leu Leu Leu Gly
 770 775 780
 Ile Phe Leu Ala Tyr Glu Thr Lys Ser Val Ser Thr Glu Lys Ile Asn
 785 790 795 800
 Asp His Arg Ala Val Gly Met Ala Ile Tyr Asn Val Ala Val Leu Cys
 805 810 815
 Leu Ile Thr Ala Pro Val Thr Met Ile Leu Ser Ser Gln Gln Asp Ala
 820 825 830

17

Ala Phe Ala Phe Ala Ser Leu Ala Ile Val Phe Ser Ser Tyr Ile Thr
 835 840 845

Leu Val Val Leu Phe Val Pro Lys Met Arg Arg Leu Ile Thr Arg Gly
 850 855 860

Glu Trp Gln Ser Glu Ala Gln Asp Thr Met Lys Thr Gly Ser Ser Thr
 865 870 875 880

Asn Asn Asn Glu Glu Lys Ser Arg Leu Leu Glu Lys Glu Asn Arg
 885 890 895

Glu Leu Glu Lys Ile Ile Ala Glu Lys Glu Glu Arg Val Ser Glu Leu
 900 905 910

Arg His Gln Leu Gln Ser Arg Gln Gln Leu Arg Ser Arg Arg His Pro
 915 920 925

Pro Thr Pro Pro Glu Pro Ser Gly Gly Leu Pro Arg Gly Pro Pro Glu
 930 935 940

Pro Pro Asp Arg Leu Ser Cys Asp Gly Ser Arg Val His Leu Leu Tyr
 945 950 955 960

Lys

<210> 8
 <211> 844
 <212> PRT
 <213> Human

<400> 8

Met Gly Pro Gly Ala Pro Phe Ala Arg Val Gly Trp Pro Leu Pro Leu
 1 5 10 15

Leu Val Val Met Ala Ala Gly Val Ala Pro Val Trp Ala Ser His Ser
 20 25 30

Pro His Leu Pro Arg Pro His Ser Arg Val Pro Pro His Pro Ser Ser
 35 40 45

Glu Arg Arg Ala Val Tyr Ile Gly Ala Leu Phe Pro Met Ser Gly Gly
 50 55 60

Trp Pro Gly Gly Gln Ala Cys Gln Pro Ala Val Glu Met Ala Leu Glu
 65 70 75 80

Asp Val Asn Ser Arg Arg Asp Ile Leu Pro Asp Tyr Glu Leu Lys Leu
 85 90 95

Ile His His Asp Ser Lys Cys Asp Pro Gly Gln Ala Thr Lys Tyr Leu
 100 105 110

Tyr Glu Leu Leu Tyr Asn Asp Pro Ile Lys Ile Ile Leu Met Pro Gly
 115 120 125

Cys Ser Ser Val Ser Thr Leu Val Ala Glu Ala Ala Arg Met Trp Asn
 130 135 140
 Leu Ile Val Leu Ser Tyr Gly Ser Ser Ser Pro Ala Leu Ser Asn Arg
 145 150 155 160
 Gln Arg Phe Pro Thr Phe Phe Arg Thr His Pro Ser Ala Thr Leu His
 165 170 175
 Asn Pro Thr Arg Val Lys Leu Phe Glu Lys Trp Gly Trp Lys Lys Ile
 180 185 190
 Ala Thr Ile Gln Gln Thr Thr Glu Val Phe Thr Ser Thr Leu Asp Asp
 195 200 205
 Leu Glu Glu Arg Val Lys Glu Ala Gly Ile Glu Ile Thr Phe Arg Gln
 210 215 220
 Ser Phe Phe Ser Asp Pro Ala Val Pro Val Lys Asn Leu Lys Arg Gln
 225 230 235 240
 Asp Ala Arg Ile Ile Val Gly Leu Phe Tyr Glu Thr Glu Ala Arg Lys
 245 250 255
 Val Phe Cys Glu Val Tyr Lys Glu Arg Leu Phe Gly Lys Lys Tyr Val
 260 265 270
 Trp Phe Leu Ile Gly Trp Tyr Ala Asp Asn Trp Phe Lys Ile Tyr Asp
 275 280 285
 Pro Ser Ile Asn Cys Thr Val Asp Glu Met Thr Glu Ala Val Glu Gly
 290 295 300
 His Ile Thr Thr Glu Ile Val Met Leu Asn Pro Ala Asn Thr Arg Ser
 305 310 315 320
 Ile Ser Asn Met Thr Ser Gln Glu Phe Val Glu Lys Leu Thr Lys Arg
 325 330 335
 Leu Lys Arg His Pro Glu Glu Thr Gly Gly Phe Gln Glu Ala Pro Leu
 340 345 350
 Ala Tyr Asp Ala Ile Trp Ala Leu Ala Leu Ala Leu Asn Lys Thr Ser
 355 360 365
 Gly Gly Gly Gly Arg Ser Gly Val Arg Leu Glu Asp Phe Asn Tyr Asn
 370 375 380
 Asn Gln Thr Ile Thr Asp Gln Ile Tyr Arg Ala Met Asn Ser Ser Ser
 385 390 395 400
 Phe Glu Gly Val Ser Gly His Val Val Phe Asp Ala Ser Gly Ser Arg
 405 410 415
 Met Ala Trp Thr Leu Ile Glu Gln Leu Gln Gly Gly Ser Tyr Lys Lys
 420 425 430

Ile Gly Tyr Tyr Asp Ser Thr Lys Asp Asp Leu Ser Trp Ser Lys Thr
 435 440 445
 Asp Lys Trp Ile Gly Gly Ser Pro Pro Ala Asp Gln Thr Leu Val Ile
 450 455 460
 Lys Thr Phe Arg Phe Leu Ser Gln Lys Leu Phe Ile Ser Val Ser Val
 465 470 475 480
 Leu Ser Ser Leu Gly Ile Val Leu Ala Val Val Cys Leu Ser Phe Asn
 485 490 495
 Ile Tyr Asn Ser His Val Arg Tyr Ile Gln Asn Ser Gln Pro Asn Leu
 500 505 510
 Asn Asn Leu Thr Ala Val Gly Cys Ser Leu Ala Leu Ala Ala Val Phe
 515 520 525
 Pro Leu Gly Leu Asp Gly Tyr His Ile Gly Arg Asn Gln Phe Pro Phe
 530 535 540
 Val Cys Gln Ala Arg Leu Trp Leu Leu Gly Leu Gly Phe Ser Leu Gly
 545 550 555 560
 Tyr Gly Ser Met Phe Thr Lys Ile Trp Trp Val His Thr Val Phe Thr
 565 570 575
 Lys Lys Glu Glu Lys Lys Glu Trp Arg Lys Thr Leu Glu Pro Trp Lys
 580 585 590
 Leu Tyr Ala Thr Val Gly Leu Leu Val Gly Met Asp Val Leu Thr Leu
 595 600 605
 Ala Ile Trp Gln Ile Val Asp Pro Leu His Arg Thr Ile Glu Thr Phe
 610 615 620
 Ala Lys Glu Glu Pro Lys Glu Asp Ile Asp Val Ser Ile Leu Pro Gln
 625 630 635 640
 Leu Glu His Cys Ser Ser Arg Lys Met Asn Thr Trp Leu Gly Ile Phe
 645 650 655
 Tyr Gly Tyr Lys Gly Leu Leu Leu Leu Leu Gly Ile Phe Leu Ala Tyr
 660 665 670
 Glu Thr Lys Ser Val Ser Thr Glu Lys Ile Asn Asp His Arg Ala Val
 675 680 685
 Gly Met Ala Ile Tyr Asn Val Ala Val Leu Cys Leu Ile Thr Ala Pro
 690 695 700
 Val Thr Met Ile Leu Ser Ser Gln Gln Asp Ala Ala Phe Ala Phe Ala
 705 710 715 720
 Ser Leu Ala Ile Val Phe Ser Ser Tyr Ile Thr Leu Val Val Leu Phe
 725 730 735

20

Val Pro Lys Met Arg Arg Leu Ile Thr Arg Gly Glu Trp Gln Ser Glu
740 745 750

Ala Gln Asp Thr Met Lys Thr Gly Ser Ser Thr Asn Asn Asn Glu Glu
755 760 765

Glu Lys Ser Arg Leu Leu Glu Lys Glu Asn Arg Glu Leu Glu Lys Ile
770 775 780

Ile Ala Glu Lys Glu Glu Arg Val Ser Glu Leu Arg His Gln Leu Gln
785 790 795 800

Ser Arg Gln Gln Leu Arg Ser Arg Arg His Pro Pro Thr Pro Pro Glu
805 810 815

Pro Ser Gly Gly Leu Pro Arg Gly Pro Pro Glu Pro Pro Asp Arg Leu
820 825 830

Ser Cys Asp Gly Ser Arg Val His Leu Leu Tyr Lys
835 840

<210> 9

<211> 3554

<212> DNA

<213> Human

<220>

<221> CDS

<222> (1)...(3234)

<400> 9

atg gca ttt tat agc tgc tgc tgg gtc ctc ttg gca ctc acc tgg cac 48
Met Ala Phe Tyr Ser Cys Cys Trp Val Leu Leu Ala Leu Thr Trp His
1 5 10 15

acc tct gcc tac ggg cca gac cag cga gcc caa aag aag ggg gac att 96
Thr Ser Ala Tyr Gly Pro Asp Gln Arg Ala Gln Lys Lys Gly Asp Ile
20 25 30

atc ctt ggg ggg ctc ttt cct att cat ttt gga gta gca gct aaa gat 144
Ile Leu Gly Gly Leu Phe Pro Ile His Phe Gly Val Ala Ala Lys Asp
35 40 45

caa gat ctc aaa tca agg ccg gag tct gtg gaa tgt atc agg tat aat 192
Gln Asp Leu Lys Ser Arg Pro Glu Ser Val Glu Cys Ile Arg Tyr Asn
50 55 60

ttc cgt ggg ttt cgc tgg tta cag gct atg ata ttt gcc ata gag gag 240
Phe Arg Gly Phe Arg Trp Leu Gln Ala Met Ile Phe Ala Ile Glu Glu
65 70 75 80

ata aac agc agc cca gcc ctt ctt ccc aac ttg acg ctg gga tac agg 288
Ile Asn Ser Ser Pro Ala Leu Leu Pro Asn Leu Thr Leu Gly Tyr Arg
85 90 95

21

ata ttt gac act tgc aac acc gtt tct aag gcc ttg gaa gcc acc ctg	336
Ile Phe Asp Thr Cys Asn Thr Val Ser Lys Ala Leu Glu Ala Thr Leu	
100 105 110	
agt ttt gtt gct caa aac aaa att gat tct ttg aac ctt gat gag ttc	384
Ser Phe Val Ala Gln Asn Lys Ile Asp Ser Leu Asn Leu Asp Glu Phe	
115 120 125	
tgc aac tgc tca gag cac att ccc tct acg att gct gtg gtg gga gca	432
Cys Asn Cys Ser Glu His Ile Pro Ser Thr Ile Ala Val Val Gly Ala	
130 135 140	
act ggc tca ggc gtc tcc acg gca gtg gca aat ctg ctg ggg ctc ttc	480
Thr Gly Ser Gly Val Ser Thr Ala Val Ala Asn Leu Leu Gly Leu Phe	
145 150 155 160	
tac att ccc cag gtc agt tat gcc tcc tcc agc aga ctc ctc agc aac	528
Tyr Ile Pro Gln Val Ser Tyr Ala Ser Ser Ser Arg Leu Leu Ser Asn	
165 170 175	
aag aat caa ttc aag tct ttc ctc cga acc atc ccc aat gat gag cac	576
Lys Asn Gln Phe Lys Ser Phe Leu Arg Thr Ile Pro Asn Asp Glu His	
180 185 190	
cag gcc act gcc atg gca gac atc atc gag tat ttc cgc tgg aac tgg	624
Gln Ala Thr Ala Met Ala Asp Ile Ile Glu Tyr Phe Arg Trp Asn Trp	
195 200 205	
gtg ggc aca att gca gct gat gac gac tat ggg cgg ccg ggg att gag	672
Val Gly Thr Ile Ala Ala Asp Asp Tyr Gly Arg Pro Gly Ile Glu	
210 215 220	
aaa ttc cga gag gaa gct gag gaa agg gat atc tgc atc gac ttc agt	720
Lys Phe Arg Glu Glu Ala Glu Glu Arg Asp Ile Cys Ile Asp Phe Ser	
225 230 235 240	
gaa ctc atc tcc cag tac tct gat gag gaa gag atc cag cat gtg gta	768
Glu Leu Ile Ser Gln Tyr Ser Asp Glu Glu Glu Ile Gln His Val Val	
245 250 255	
gag gtg att caa aat tcc acg gcc aaa gtc atc gtg gtt ttc tcc agt	816
Glu Val Ile Gln Asn Ser Thr Ala Lys Val Ile Val Val Phe Ser Ser	
260 265 270	
ggc cca gat ctt gag ccc ctc atc aag gag att gtc cgg cgc aat atc	864
Gly Pro Asp Leu Glu Pro Leu Ile Lys Glu Ile Val Arg Arg Asn Ile	
275 280 285	
acg ggc aag atc tgg ctg gcc agc gag gcc tgg gcc agc tcc tcc ctg	912
Thr Gly Lys Ile Trp Leu Ala Ser Glu Ala Trp Ala Ser Ser Ser Leu	
290 295 300	
atc gcc atg cct cag tac ttc cac gtg gtt ggc ggc acc att gga ttc	960
Ile Ala Met Pro Gln Tyr Phe His Val Val Gly Gly Thr Ile Gly Phe	
305 310 315 320	

gct ctg aag gct ggg cag atc cca ggc ttc cgg gaa ttc ctg aag aag	1008
Ala Leu Lys Ala Gly Gln Ile Pro Gly Phe Arg Glu Phe Leu Lys Lys	
325 330 335	
gtc cat ccc agg aag tct gtc cac aat ggt ttt gcc aag gag ttt tgg	1056
Val His Pro Arg Lys Ser Val His Asn Gly Phe Ala Lys Glu Phe Trp	
340 345 350	
gaa gaa aca ttt aac tgc cac ctc caa gaa ggt gca aaa gga cct tta	1104
Glu Glu Thr Phe Asn Cys His Leu Gln Glu Gly Ala Lys Gly Pro Leu	
355 360 365	
cct gtg gac acc ttt ctg aga ggt cac gaa gaa agt ggc gac agg ttt	1152
Pro Val Asp Thr Phe Leu Arg Gly His Glu Glu Ser Gly Asp Arg Phe	
370 375 380	
agc aac agc tcg aca gcc ttc cga ccc ctc tgt aca ggg gat gag aac	1200
Ser Asn Ser Ser Thr Ala Phe Arg Pro Leu Cys Thr Gly Asp Glu Asn	
385 390 395 400	
atc agc agt gtc gag acc cct tac ata gat tac acg cat tta cgg ata	1248
Ile Ser Ser Val Glu Thr Pro Tyr Ile Asp Tyr Thr His Leu Arg Ile	
405 410 415	
tcc tac aat gtg tac tta gca gtc tac tcc att gcc cac gcc ttg caa	1296
Ser Tyr Asn Val Tyr Leu Ala Val Tyr Ser Ile Ala His Ala Leu Gln	
420 425 430	
gat ata tat acc tgc tta cct ggg aga ggg ctc ttc acc aat ggc tcc	1344
Asp Ile Tyr Thr Cys Leu Pro Gly Arg Gly Leu Phe Thr Asn Gly Ser	
435 440 445	
tgt gca gac atc aag aaa gtt gag gcg tgg cag gtc ctg aag cac cta	1392
Cys Ala Asp Ile Lys Lys Val Glu Ala Trp Gln Val Leu Lys His Leu	
450 455 460	
cgg cat cta aac ttt aca aac aat atg ggg gag cag gtg acc ttt gat	1440
Arg His Leu Asn Phe Thr Asn Asn Met Gly Glu Gln Val Thr Phe Asp	
465 470 475 480	
gag tgt ggt gac ctg gtg ggg aac tat tcc atc atc aac tgg cac ctc	1488
Glu Cys Gly Asp Leu Val Gly Asn Tyr Ser Ile Ile Asn Trp His Leu	
485 490 495	
tcc cca gag gat ggc tcc atc gtg ttt aag gaa gtc ggg tat tac aac	1536
Ser Pro Glu Asp Gly Ser Ile Val Phe Lys Glu Val Gly Tyr Tyr Asn	
500 505 510	
gtc tat gcc aag aag gga gaa aga ctc ttc atc aac gag gag aaa atc	1584
Val Tyr Ala Lys Lys Gly Glu Arg Leu Phe Ile Asn Glu Glu Lys Ile	
515 520 525	
ctg tgg agt ggg ttc tcc agg gag gtg ccc ttc tcc aac tgc agc cga	1632
Leu Trp Ser Gly Phe Ser Arg Glu Val Pro Phe Ser Asn Cys Ser Arg	
530 535 540	

gac tgc ctg gca ggg acc agg aaa ggg atc att gag ggg gag ccc acc	1680
Asp Cys Leu Ala Gly Thr Arg Lys Gly Ile Ile Glu Gly Glu Pro Thr	
545 550 555 560	
tgc tgc ttt gag tgt gtg gag tgt cct gat ggg gag tat agt gat gag	1728
Cys Cys Phe Glu Cys Val Glu Cys Pro Asp Gly Glu Tyr Ser Asp Glu	
565 570 575	
aca gat gcc agt gcc tgt aac aag tgc cca gat gac ttc tgg tcc aat	1776
Thr Asp Ala Ser Ala Cys Asn Lys Cys Pro Asp Asp Phe Trp Ser Asn	
580 585 590	
gag aac cac acc tcc tgc att gcc aag gag atc gag ttt ctg tgc tgg	1824
Glu Asn His Thr Ser Cys Ile Ala Lys Glu Ile Glu Phe Leu Ser Trp	
595 600 605	
acg gag ccc ttt ggg atc gca ctc acc ctc ttt gcc gtg ctg ggc att	1872
Thr Glu Pro Phe Gly Ile Ala Leu Thr Leu Phe Ala Val Leu Gly Ile	
610 615 620	
ttc ctg aca gcc ttt gtg ctg ggt gtg ttt atc aag ttc cgc aac aca	1920
Phe Leu Thr Ala Phe Val Leu Gly Val Phe Ile Lys Phe Arg Asn Thr	
625 630 635 640	
ccc att gtc aag gcc acc aac cga gag ctc tcc tac ctc ctc ctc ttc	1968
Pro Ile Val Lys Ala Thr Asn Arg Glu Leu Ser Tyr Leu Leu Leu Phe	
645 650 655	
tcc ctg ctc tgc tgc ttc tcc agc tcc ctg ttc ttc atc ggg gag ccc	2016
Ser Leu Leu Cys Cys Phe Ser Ser Ser Leu Phe Phe Ile Gly Glu Pro	
660 665 670	
cag gac tgg acg tgc cgc ctg cgc cag ccg gcc ttt ggc atc agc ttc	2064
Gln Asp Trp Thr Cys Arg Leu Arg Gln Pro Ala Phe Gly Ile Ser Phe	
675 680 685	
gtg ctc tgc atc tca tgc atc ctg gtg aaa acc aac cgt gtc ctc ctg	2112
Val Leu Cys Ile Ser Cys Ile Leu Val Lys Thr Asn Arg Val Leu Leu	
690 695 700	
gtg ttt gag gcc aag atc ccc acc agc ttc cac cgc aag tgg tgg ggg	2160
Val Phe Glu Ala Lys Ile Pro Thr Ser Phe His Arg Lys Trp Trp Gly	
705 710 715 720	
ctc aac ctg cag ttc ctg ctg gtt ttc ctc tgc acc ttc atg cag att	2208
Leu Asn Leu Gln Phe Leu Leu Val Phe Leu Cys Thr Phe Met Gln Ile	
725 730 735	
gtc atc tgt gtg atc tgg ctc tac acc gcg ccc ccc tca agc tac cgc	2256
Val Ile Cys Val Ile Trp Leu Tyr Thr Ala Pro Pro Ser Ser Tyr Arg	
740 745 750	
aac cag gag ctg gag gat gag atc atc ttc atc acg tgc cac gag ggc	2304
Asn Gln Glu Leu Glu Asp Glu Ile Ile Phe Ile Thr Cys His Glu Gly	
755 760 765	

24

tcc ctc atg gcc ctg ggc ttc ctg atc ggc tac acc tgc ctg ctg gct Ser Leu Met Ala Leu Gly Phe Leu Ile Gly Tyr Thr Cys Leu Leu Ala 770 775 780	2352
gcc atc tgc ttc ttc ttt gcc ttc aag tcc cgg aag ctg ccg gag aac Ala Ile Cys Phe Phe Phe Ala Phe Lys Ser Arg Lys Leu Pro. Glu Asn 785 790 795 800	2400
ttc aat gaa gcc aag ttc atc acc ttc agc atg ctc atc ttc ttc atc Phe Asn Glu Ala Lys Phe Ile Thr Phe Ser Met Leu Ile Phe Phe Ile 805 810 815	2448
gtc tgg atc tcc ttc att cca gcc tat gcc agc acc tat ggc aag ttt Val Trp Ile Ser Phe Ile Pro Ala Tyr Ala Ser Thr Tyr Gly Lys Phe 820 825 830	2496
gtc tct gcc gta gag gtg att gcc atc ctg gca gcc agc ttt ggc ttg Val Ser Ala Val Glu Val Ile Ala Ile Leu Ala Ala Ser Phe Gly Leu 835 840 845	2544
ctg gcg tgc atc ttc ttc aac aag atc tac atc att ctc ttc aag cca Leu Ala Cys Ile Phe Phe Asn Lys Ile Tyr Ile Ile Leu Phe Lys Pro 850 855 860	2592
tcc cgc aac acc atc gag gag gtg cgt tgc agc acc gca gct cac gct Ser Arg Asn Thr Ile Glu Glu Val Arg Cys Ser Thr Ala Ala His Ala 865 870 875 880	2640
ttc aag gtg gct gcc cgg gcc acg ctg cgc cgc agc aac gtc tcc cgc Phe Lys Val Ala Arg Ala Thr Leu Arg Arg Ser Asn Val Ser Arg 885 890 895	2688
aag cgg tcc agc agc ctt gga ggc tcc acg gga tcc acc ccc tcc tcc Lys Arg Ser Ser Ser Leu Gly Gly Ser Thr Gly Ser Thr Pro Ser Ser 900 905 910	2736
tcc atc agc agc aag agc aac agc gaa gac cca ttc cca cag ccc gag Ser Ile Ser Ser Lys Ser Asn Ser Glu Asp Pro Phe Pro Gln Pro Glu 915 920 925	2784
agg cag aag cag cag cag ccg ctg gcc cta acc cag caa gag cag cag Arg Gln Lys Gln Gln Gln Pro Leu Ala Leu Thr Gln Gln Glu Gln Gln 930 935 940	2832
cag cag ccc ctg acc ctc cca cag cag caa cga tct cag cag cag ccc Gln Gln Pro Leu Thr Leu Pro Gln Gln Gln Arg Ser Gln Gln Gln Pro 945 950 955 960	2880
aga tgc aag cag aag gtc atc ttt ggc agc ggc acg gtc acc ttc tca Arg Cys Lys Gln Lys Val Ile Phe Gly Ser Gly Thr Val Thr Phe Ser 965 970 975	2928
ctg agc ttt gat gag cct cag aag aac gcc atg gcc cac ggg aat tct Leu Ser Phe Asp Glu Pro Gln Lys Asn Ala Met Ala His Gly Asn Ser 980 985 990	2976

acg cac cag aac tcc ctg gag gcc cag aaa agc agc gat acg ctg acc	3024
Thr His Gln Asn Ser Leu Glu Ala Gln Lys Ser Ser Asp Thr Leu Thr	
995 1000 1005	
cga cac cag cca tta ctc ccg ctg cag tgc ggg gaa acg gac tta gat	3072
Arg His Gln Pro Leu Leu Pro Leu Gln Cys Gly Glu Thr Asp Leu Asp	
1010 1015 1020	
ctg acc gtc cag gaa aca ggt ctg caa gga cct gtg ggt gga gac cag	3120
Leu Thr Val Gln Glu Thr Gly Leu Gln Gly Pro Val Gly Gly Asp Gln	
1025 1030 1035 1040	
cgg cca gag gtg gag gac cct gaa gag ttg tcc cca gca ctt gta gtg	3168
Arg Pro Glu Val Glu Asp Pro Glu Glu Leu Ser Pro Ala Leu Val Val	
1045 1050 1055	
tcc agt tca cag agc ttt gtc atc agt ggt gga ggc agc act gtt aca	3216
Ser Ser Ser Gln Ser Phe Val Ile Ser Gly Gly Gly Ser Thr Val Thr	
1060 1065 1070	
gaa aac gta gtg aat tca	3234
Glu Asn Val Val Asn Ser	

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/07352

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07K14/47 C07K14/705 C12N15/12 C07K16/28 C12N5/06
A01K67/027

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 46675 A (NOVARTIS AG) 11 December 1997 (1997-12-11) cited in the application abstract page 6, paragraph 2 -page 7, paragraph 1 page 16, paragraph 2 -page 21, paragraph 2; examples 1-10	1-33
X	KAUPMANN K ET AL: "EXPRESSION CLONING OF GABAB RECEPTORS UNCOVERS SIMILARITY TO METABOTROPIC GLUTAMATE RECEPTORS" NATURE, vol. 386, no. 6622, 20 March 1997 (1997-03-20), pages 239-246, XP002032306 ISSN: 0028-0836 cited in the application the whole document	1-24, 26-29

	--- -/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

23 September 1999

Date of mailing of the international search report

08/10/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Mateo Rosell, A.M.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/07352

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	JONES, K.A. ET AL., : "GABAB receptors function as heteromeric assembly of the subunits GABABR1 and GABABR2" NATURE, vol. 396, 17 December 1998 (1998-12-17), pages 674-679, XP002116148 cited in the application page 677, right-hand column, paragraph 2 -page 678, left-hand column, paragraph 1; figures 1A,2	1-4, 15-17, 24,25, 28-32
P,X	WHITE J.H. ET AL., : "Heterodimerization is required for the formation of a functional GABAB receptor." NATURE, vol. 396, 17 December 1998 (1998-12-17), page 679-682 XP002116149 abstract; figures 1,4 page 681, left-hand column, last paragraph -page 682, right-hand column, paragraph 1	1-4, 15-17, 28-32
P,X	KAUPMANN K. ET AL., : "GABAB-receptor subtypes assemble into functional heteromeric complexes" NATURE, vol. 396, 17 December 1998 (1998-12-17), pages 683-687, XP002105268 abstract; figures 1,2	1-4, 15-17, 24,25, 28-32
P,X	DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 10 October 1998 (1998-10-10), XP002114719 HINXTON, GB AC= AF056085. Homo sapiens GABA-B receptor mRNA, complete cds. from nt 458 abstract	1-4, 15-17
P,X	DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 21 December 1998 (1998-12-21), XP002116150 HINXTON, GB AC= AF074483. Homo sapiens GABA-B receptor 2 mRNA, complete cds. abstract	5-9, 18-23
P,X	DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 4 January 1999 (1999-01-04), XP002116151 HINXTON, GB AC = AF069755. Homo sapiens orphan G protein-coupled receptor HG20 (HG20) mRNA, complete cds.	1-4, 15-17

INTERNATIONAL SEARCH REPORT

International Application No

PC f/US 99/07352

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 99 20751 A (BOROWSKY BETH ; JONES KENNETH A (US); LAZ THOMAS M (US); SYNAPTIC P) 29 April 1999 (1999-04-29) fig 1a-e abstract page 6-19 page 91, line 1 -page 123, line 6	1-24, 26-33
E	EP 0 937 777 A (SMITHKLINE BEECHAM PLC ; SMITHKLINE BEECHAM CORP (US)) 25 August 1999 (1999-08-25) see SEQ.ID.N.1 and 3. abstract page 3, line 10-25 page 6, line 44 -page 11, line 11 -----	1-24, 26-32

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 99/07352

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9746675 A	11-12-1997	AU 2028497 A CA 2254862 A EP 0907731 A	05-01-1998 11-12-1997 14-04-1999
WO 9920751 A	29-04-1999	AU 1101099 A	10-05-1999
EP 0937777 A	25-08-1999	WO 9942580 A WO 9942603 A	26-08-1999 26-08-1999